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Central serous chorioretinopathy (CSCR) is a major cause of vision threat among middle-aged male in-
dividuals. Multimodal imaging led to the description of a wide range of CSCR manifestations, and
highlighted the contribution of the choroid and pigment epithelium in CSCR pathogenesis. However, the
exact molecular mechanisms of CSCR have remained uncertain. The aim of this review is to recapitulate
the clinical understanding of CSCR, with an emphasis on the most recent ﬁndings on epidemiology, risk
factors, clinical and imaging diagnosis, and treatments options. It also gives an overview of the novel
mineralocorticoid pathway hypothesis, from animal data to clinical evidences of the biological efﬁcacy of
oral mineralocorticoid antagonists in acute and chronic CSCR patients. In rodents, activation of the
mineralocorticoid pathway in ocular cells either by intravitreous injection of its speciﬁc ligand, aldo-
sterone, or by over-expression of the receptor speciﬁcally in the vascular endothelium, induced ocular
phenotypes carrying many features of acute CSCR. Molecular mechanisms include expression of the
calcium-dependent potassium channel (KCa2.3) in the endothelium of choroidal vessels, inducing sub-
sequent vasodilation. Inappropriate or over-activation of the mineralocorticoid receptor in ocular cells
and other tissues (such as brain, vessels) could link CSCR with the known co-morbidities observed in
CSCR patients, including hypertension, coronary disease and psychological stress.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Central serous chorioretinopathy (CSCR or CSC) is a posterior
segment disease characterized by localized and limited serous de-
tachments of the neurosensory retina often associated with focal
detachments of an altered retinal pigment epithelium. The term
“central” refers to the form of the disease causing visual symptoms
due to the presence of serous detachments in the macular area. But
asymptomatic subjects may have presented one or multiple epi-
sodes of extra macular serous detachments, as often observed in
the contralateral eye of an active CSCR patient or when systemat-
ically examining relatives of CSCR patients (Lehmann et al., 2015;
Weenink et al., 2001) (Figs. 1 and 5D). The prevalence of CSCR is
therefore likely to have been underestimated.
Whilst the acute CSCR form is clinically obvious especially in
middle-aged men, the clinical diagnosis in older patients is more
challenging, as chronic CSCR often resembles age-related macular
degeneration (AMD) or can be complicated by choroidal neo-
vascularization (CNV) (Fung et al., 2012; Inhoffen et al., 2012; Pang
and Freund, 2015; Schatz et al., 1992). CSCR diagnosis is also difﬁ-
cult when occurring secondarily to steroid treatments adminis-
tered for other retinal diseases (Khairallah et al., 2012). Recently,
enhanced visualization of the choroid with spectral-domain optical
coherence tomography (SD-OCT) has facilitated a more robust
assessment of the role played by the choroid in CSCR, which in the
past ﬁve years has resulted in more than 100 publications (Mrejen
and Spaide, 2013). Based on these observations, it was recently
proposed that “pachychoroid pigment epitheliopathy” could be a
subclinical phenotype potentially complicated by serous de-
tachments and/or choroidal vasculopathy, including type 1 CNV
and polypoidal vasculopathy (Pang and Freund, 2015; Warrow
et al., 2013). The segregation of the CSCR phenotypes becomesunclear. In particular, whether there is a continuum between acute
simple CSCR associated or not with pachychoroid (Fig. 2), and the
chronic variants of the disease (referred to as Diffuse Retinal
Pigment Epitheliopathy, DRPE) is yet to be prospectively investi-
gated. Sparse or unique acute episodes of CSCR have a favorable
visual prognosis but DRPE is associated with progressive and
bilateral vision impairment, and has been estimated as the fourth
most frequent non-surgical retinopathy (Wang et al., 2008). To
date, the genetic, environmental, biological or clinical factors that
favor one or the other form of this disease have not been
established.
The relation between CSCR and corticoids is probably one of the
most intriguing aspects of the disease. Glucocorticoids efﬁciently
reduce macular edema of many origins, evenwhen associated with
subretinal ﬂuid (Noma et al., 2012; Ossewaarde-van Norel et al.,
2011), but glucocorticoids can aggravate subretinal ﬂuid accumu-
lation in CSCR patients. Even exposure to low-dose non-ocular
corticosteroids has been associated with the occurrence of CSCR
(Bouzas et al., 2002; Thinda et al., 2015). But high-dose intraocular
injection of glucocorticoids, routinely administered for the treat-
ment of macular edema, has not been associated with increased
incidence of CSCR. Such discrepancies reﬂect the still non-
elucidated complexity of steroids regulation on ocular
physiopathology.
Since glucocorticoids aggravate rather than improve CSCR,
inﬂammation was disregarded among potential disease mecha-
nisms. This should be re-examined from the time when inﬂam-
mation is recognized as a key player in the pathogenesis of AMD, in
which unexpectedly glucocorticoid treatments did not show any
major beneﬁt (Geltzer et al., 2013).
Speciﬁc psychological and personality proﬁles have been asso-
ciated with CSCR (Piskunowicz et al., 2014; Yannuzzi, 1986) but the
Fig. 1. Acute central serous chorioretinopathy with asymptomatic involvement of the contralateral eye. Thirty-nine year old man complaining of blurred central vision in his left eye
for 2 weeks. Midphase ﬂuorescein angiogram (A) identiﬁes a single leaking point (arrow). Near-infrared reﬂectance (B) shows a circular hyporeﬂectivity corresponding to the
subretinal detachment, involving the fovea as conﬁrmed by SD-OCT (C). The same imaging of his asymptomatic right eye (D, E and F, respectively) revealed an extrafoveal unnoticed
subretinal detachment, associated to a leakage point (star) and an area of RPE defect, probably resulting from a previous episode.
A. Daruich et al. / Progress in Retinal and Eye Research 48 (2015) 82e11884exact link between anxiety-sensitive personalities and steroid
biology has not been elucidated and the full ocular and systemic
steroid hormonal proﬁle of CSCR patients has been only partially
explored (Zakir et al., 2009). More determinants should be now
considered in light of recent discoveries linking stress,Fig. 2. Acute central serous chorioretinopathy in two cases, with increased and normal ch
increased choroidal thickness (measured subfoveally at 560 mm) and eroded photorecept
detachment. (B) SD-OCT of a 36-year old male patient with normal refractive status showin
leakage site (arrow) evidenced by ﬂuorescein angiography (C), a diminished fundus autoﬂ
modiﬁcations. Autoﬂuorescence was globally increased over the detached area due to the a
segments.corticosteroids, epigenetic modiﬁcations and cardiovascular risk
factors (Hunter, 2012; Reynolds, 2013).
All this considered, it is clear that complex links between CSCR
and corticosteroids are yet to be described. In this context, we have
investigated and identiﬁed the mineralocorticoid receptor as aoroidal thickness. (A) SD-OCT in a 32-year old male patient with acute CSCR showing
or outer segments over the leakage site (star), visible as a small pigment epithelial
g acute CSCR and a subfoveal choroidal thickness within normal range (181 mm). At the
uoresence (D) and a moderate increased infrared reﬂectance (E) indicated local RPE
ccumulation of autoﬂuorescent material in the non-phagocytized photoreceptor outer
Fig. 3. Multimodal imaging of active chronic CSCR in the right eye of a 45-year old man. FAF showed hypo-autoﬂuorescent gravitational tracks (A). FA revealed a corresponding
increased transmission of ﬂuorescence related to the extended RPE alterations, and an active leakage site (arrow) corresponding to the RPE elevation on EDI-OCT (H, star). ICG
showed dilated choroidal vessels and hyperpermeability (D, E), and late hyperﬂuorescence of the leakage site (F). EDI-OCT (H) visualized a RPE elevation and a hyper-reﬂective ﬂow
within the subretinal ﬂuid. Beneath the RPE elevation, the choroidal vessels were more dilated, with hyper-reﬂective walls, and the choriocapillaris was thinner than in adjacent
areas (star). FAF: fundus autoﬂuorescence; FA: ﬂuorescein angiography; ICG: indocyanine green angiography; IR: infrared reﬂectance; EDI-OCT: enhance-depth imaging optical
coherence tomography.
A. Daruich et al. / Progress in Retinal and Eye Research 48 (2015) 82e118 85potential player in CSCR pathogenesis. This review will focus on
recent ﬁndings that have furthered the epidemiology, the clinical
understanding and the management of CSCR and will detail the
possible role of the mineralocorticoid pathway in CSCR pathogen-
esis and treatment.
2. General overview of CSCR
Several comprehensive reviews dealing with CSCR diagnosis,
pathophysiology and therapeutic interventions have been recently
published (Liew et al., 2013; Nicholson et al., 2013; Quin et al., 2013;
Ross et al., 2011). We will therefore focus on the more recent
ﬁndings and debated issues regarding CSCR. General and essential
evidence-based knowledge will be compiled in tables to facilitate a
broad overview of the available literature.
2.1. Epidemiology
CSCR ranks among the most common vision-threatening reti-
nopathies after AMD, diabetic retinopathy and branch retinal vein
occlusion (Wang et al., 2008). A higher prevalence among menwas
observed in several studies, with 72%e88% of cases occurring in
male subjects (Spaide et al., 1996a; Tittl et al., 1999). In a
population-based study carried out in Olmsted County, Minnesota,the reported annual incidence was 9.9 per 100,000 individuals for
men and 1.7 for women, indicating a 6-times higher incidence in
men than in women (Kitzmann et al., 2008).
There is a variability in the reported age of affected patients, the
more recent epidemiological data reporting a highermean age than
generally assumed, ranging between 39 and 51 years (Kitzmann
et al., 2008; Tsai et al., 2013a). CSCR can occur at later ages,
particularly in women and patients affected by atypical chronic
forms (Cohen et al., 1983; Kitzmann et al., 2008; Lafaut et al., 1998;
Perkins et al., 2002; Quillen et al., 1996). Noteworthy, CSCR has been
rarely reported in children (Kim et al., 2012).
Variations of CSCR incidence among various ethnic groups
remain controversial. A suspected higher frequency among Asians,
Caucasians and Hispanics as compared to African Americans (Chan
et al., 2010; Yannuzzi, 1987) was not conﬁrmed in all studies (Desai
et al., 2003). A more severe form of CSCR with lower visual acuity
seems to affect the African American subjects. In the Asian popu-
lation, CSCR is frequent and severe, with bilateral and multifocal
forms being reported more frequently than in other ethnic groups
(How and Koh, 2006). In a Taiwanese population-based study, the
mean annual incidence of non-steroid induced CSCR was 21/
100,000 (twice the incidence reported in Olmsted County, Minne-
sota) with a male/female ratio of 1.74. The incidence was highest in
the 35e39 year-old age group, followed by the 40e44 year-old
Fig. 4. Multimodal imaging of inactive chronic CSCR in the left eye of a 45-year old man (same patient as Fig. 3). FAF exhibited two circular patchy areas of increased auto-
ﬂuorescence related to previous CSCR episodes (A). FA revealed two areas of mild residual RPE window defect (B, C). ICG showed two areas of persistent hyperpermeability (D, E)
during early and midphase, with centrifugal expansion and central hypoﬂuorescence at late phase. EDI-OCT conﬁrmed the absence of active episode (H). It also showed a
pachychoroid with dilated choroidal vessels, and a mild photoreceptor outer segments atrophy (between arrows and dotted lines). This atrophy corresponded partially to the hyper-
autoﬂuorescence (A), possibly via a window defect in photopigment density. FAF: fundus autoﬂuorescence; FA: ﬂuorescein angiography; ICG: indocyanine green angiography; IR:
infrared reﬂectance; EDI-OCT: enhance-depth imaging optical coherence tomography.
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this difference was signiﬁcant only in the younger age groups,
suggesting that women present CSCR at older ages (Tsai et al.,
2013a). Finally, in the Asian population, large pigment epithelial
detachments and highly elevated serous retinal detachments are
more frequently observed, whichmight bemisdiagnosed as Harada
disease and aggravated by high-dose systemic corticosteroids
(Kunavisarut et al., 2009).
2.2. Risk factors
2.2.1. Genetic predisposition
Several sporadic cases of familial CSCR have been reported in the
literature (Amalric et al., 1971; Haik et al., 1968; Lin et al., 2000;
Oosterhuis, 1996; Park et al., 1998; Wyman, 1963). Stronger evi-
dence for a genetic contribution to the pathogenesis of CSCR comes
from the observation that in 14 out of 27 families of CSCR patients
(52%), at least one relative presented multiple areas of RPE atrophy
or fundus lesions suggestive of chronic CSCR (Weenink et al., 2001).
To date, no clear transmission pattern and no speciﬁc genotype
have been associated to CSCR. In a recent analysis of ﬁve families,
50% of the eyes from relatives of CSCR patients had a choroid
thicker than 395 mm, suggesting that pachychoroid could be an
inherited condition with a possible dominant transmission pattern(Lehmann et al., 2015).
If conﬁrmed, this hypothesis would suggest that a genetic
background may predispose to CSCR and that thick choroids could
be one of its phenotypic indicators.
Genetic studies based on single nucleotide polymorphisms have
been performed on different cohorts of CSCR subjects. Complement
factor H (CFH) was chosen as a candidate susceptibility gene for
CSCR because the protein binds to adrenomedullin, a peptide that
belongs to the calcitonin family and elicits a vasodilator action on
the choroid. An association was found in 5 common poly-
morphisms of the CFH gene in a group of 140 Asian CSCR cases
(compared to 934 population-based and 335 hospital-based con-
trols), suggesting in this population a potential involvement of CFH
in CSCR pathogenesis (Miki et al., 2013). In a larger cohort of 292
chronic CSCR patients (compared to 1147 AMD cases and 1311
healthy individuals), single nucleotide polymorphisms at 19 loci
previously associated with AMD have been investigated. An asso-
ciation of chronic CSCR with genetic variants in ARMS2 and CFH
was demonstrated, suggesting a genetic and pathogenic overlap
between chronic CSCR and AMD (De Jong et al., 2014). However, in
this study, alleles in ARMS2 and CFH that confer risks for AMDwere
protective for CSCR and alleles in CFH that were protective for AMD
were associated to CSCR.
Interestingly, we have analyzed the subretinal ﬂuid obtained
Fig. 5. Spectrum of choroidal changes in central serous chorioretinopathy on enhanced-depth imaging SD-OCT. (A) Increased subfoveal choroidal thickness (480 mm) with dilatation
of large vessels from Haller's layer (arrows) and compression of overlying choriocapillaris (star), at the level of the subretinal detachment. (B) Increased subfoveal choroidal thickness
(566 mm) without compression of the choriocapillaris. Hyporeﬂective dilated choroidal vessel (arrow) underlying a leakage site with a RPE elevation and locally thickened neuro-
sensory retina (“retinal dipping”, star), connected by an hyper-reﬂective ﬂow, suggesting a high ﬁbrin or protein content. (C) Dilated choroidal vessels despite normal subfoveal
choroidal thickness (295 mm) in a resolved CSCR case. Beneath the pigment epithelial detachment, a hyporeﬂective choroidal vessel with square borders is visible, most likely a
reﬂectivity artifact due to choroidal ﬂow changes. (D) Asymptomatic fellow eye in a patient with unilateral active CSCR exhibiting a thickened choroid (subfoveally, 661 mm) despite a
moderate dilation of choroidal vessels, and an extrafoveal pigment epithelial detachment. (E) Vertical enhanced depth imaging SD-OCT section showing a pronounced, diffuse
dilatation of large and medium choroidal vessels. (F) Extremely increased subfoveal choroidal thickness (675 mm) and dilated large vessel spanning the whole choroid (star) with thin
hyper-reﬂective vascular walls (box) suggesting parietal structural changes. Shallowwavy RPE detachment and intraretinal cystoid cavities indicate chronic CSCR. (G) Magniﬁcation of
case F demonstrating hyper-reﬂective dots at the level of choriocapillaris (box). (H) Magniﬁcation of case F showing 2 months later partial reapplication of the detached neurosensory
retina. There is a rarefaction and a displacement of the choroidal hyper-reﬂective dots (box), possibly reﬂecting a cellular process related to the disease activity.
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and lower levels of all other complement fractions compared to the
subretinal ﬂuid of control patients with rhegmatogenous retinal
detachments (unpublished personal data). This observation is in
agreement with the previous genetic ﬁndings.
Finally, in a cohort of 400 CSCR cases (compared to 1400
matched controls), a signiﬁcant association was found with 4
common cadherin 5 single-nucleotide polymorphisms in CSCR
male patients. Since cadherin 5 contributes to intercellular adhe-
sions in the vascular endothelium, and is down-regulated by cor-
ticosteroids, genetic variations in cadherin 5, combined with
triggering events such as corticosteroid treatment, could explain a
proportion of CSCR occurrences among male patients (Schubert
et al., 2014).
2.2.2. Cardiovascular diseases and hypertension
Patients with hypertension have a higher risk of developing
CSCR (Odds Ratio (OR): 2.25e2.3) (Eom et al., 2012; Tittl et al.,
1999). As compared to control patients, males with CSCR have asigniﬁcantly higher rate of coronary heart disease (Hazard Ratio
(HR): 1.72), indicating that CSCR may be a potential risk factor for
the development of coronary heart disease in men (Chen et al.,
2014). CSCR was also shown to be an independent risk factor for
ischemic stroke (HR: 1.56; 95% conﬁdence interval (CI), 1.11e2.18)
(Tsai et al., 2012), and for organic and psychogenic erectile
dysfunction (HR: 2.14; 95% CI, 1.34e3.44 and 3.83; 95% CI,
1.47e10.01, respectively) (Tsai et al., 2013b). Consequently, the
choroidal vasculopathy described in CSCR may not be isolated but
rather part of a more diffuse vascular dysfunction that is yet to be
better characterized.
2.2.3. Sympathetic-parasympathetic activity and reactivity
Compared to healthy subjects, CSCR patients present a signiﬁ-
cant sympathetic-parasympathetic imbalance. There is sympa-
thetic over-activation and a decreased parasympathetic activity, as
assessed by measures of blood pressure and heart rate variability
(Tewari et al., 2006). This may be related to the modulation of the
choroidal blood ﬂow by the autonomic nervous system, and
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epinephrine on RPE cells, ultimately leading to apoptosis (Sibayan
et al., 2000).
2.2.4. Corticosteroids
CSCR patients are more likely to have been previously exposed
to oral corticosteroid medications, and patients under corticoste-
roid therapy are at higher risk for developing CSCR (Carvalho-
Recchia et al., 2002; Haimovici et al., 2004; Karadimas and
Bouzas, 2004; Kitzmann et al., 2008; Tittl et al., 1999; Tsai et al.,
2014; Wakakura et al., 1997). When considering the route of
administration, most series have clearly reported that systemic
intake (oral or intravenous) is an independent risk factor for CSCR
(Haimovici et al., 2004; Tittl et al., 1999; Tsai et al., 2014;
Wakakura et al., 1997). CSCR has also been described after local
administration of corticosteroids via the following routes: inhaled
and intranasal (Haimovici et al., 1997; Kleinberger et al., 2011),
epidural (Iida et al., 2001; Kao, 1998; Pizzimenti and Daniel, 2005),
intra-articular (Hurvitz et al., 2009; Kassam et al., 2011; Mondal
et al., 2005), topical dermal (Ezra et al., 2011; Fernandez et al.,
2004; Karadimas and Bouzas, 2004; Romero et al., 2005) and
periocular (Baumal et al., 2004). Whether intraocular steroids
induce CSCR remains to be demonstrated. The aggravation of a
pre-existing CSCR and the induction of a CSCR after vitrectomy
and triamcinilone injection have been described in two case re-
ports (Imasawa et al., 2005; Kocabora et al., 2008). A systematic
literature search of corticosteroid-induced CSCR reports is sum-
marized in Table 1, indicating the incriminated drugs, routes of
intake and doses.
Systemic corticosteroids have been associated with occurrences,
prolongation, exacerbation and recurrences of CSCR (Khairallah
et al., 2012). Steroid-induced CSCR has less male predilection
than idiopathic CSCR, and has frequently a bilateral and atypical
presentation (Bouzas et al., 2002; Khairallah et al., 2012). It wasTable 1
Corticosteroids-induced CSCR.
Route Type of corticosteroid Dose
Oral Prednisolone 5e60 mg
Prednisone 10e80 m
Intravenous Betamethasone 10 mg/d
Methylprednisolone 16e1000
Intravitreous Triamcinolone acetonide 4 mg/0.1
Epidural Triamcinolone acetonide
Methylprednisolone acetate
2 mL Tri
40e120
Periocular Triamcinolone acetonide 1.0-mL(4
Dermal Mometasone furoate 0.1%
Bethamethasone þ calcitriol
0.1% (mo
NA
Intra-articular Triamcinolone acetonide 1e2 ml (
Intranasal Fluticasone propionate
Beclomethasone
NA
NA ¼ Data not provided.suggested that steroid-induced CSCR may be related to an idio-
syncratic response in selected vulnerable individuals rather than to
a dose-dependent effect, since very low doses can induce CSCR
episodes (Han et al., 2014). During corticosteroid treatment for
posterior uveitis, the discrimination between steroid-induced se-
rous retinal detachments and uveitis-related manifestations can be
challenging (Khairallah et al., 2012). Some studies have suggested
that concomitant use of steroid and catecholamines may have ad-
ditive effects in animal models of serous retinal detachment
(Falkenstein et al., 2000; Jampol et al., 2002; Walker et al., 1996;
Yoshioka et al., 1982). Organ transplant procedures require treat-
ments with high doses of glucocorticoids and vasopressive cate-
cholamines and stimulate the endogenous production of stress
hormones increasing the risk of CSCR. Indeed, there are numerous
reports of CSCR following organ transplantation, the more
frequently involved interventions being: kidney, bone marrow and
heart transplantations (Chaine et al., 2001; Cheng et al., 2002;
Chung et al., 2007; Farzan et al., 2014; Fawzi et al., 2006; Fawzi
and Cunningham, 2001; Friberg and Eller, 1990; Kamoun et al.,
2005; Karashima et al., 2002; Kian-Ersi et al., 2008; Moon and
Mieler, 2003; Oliaei et al., 2007; Polak et al., 1995; Sabet-Peyman
et al., 2012; Singh et al., 2003). Finally, allergy has been suggested
to favor CSCR, yet various allergic manifestations are managedwith
local or systemic corticosteroids and the distinction between the
contribution of allergy or its treatment remains to be determined
(Edalati et al., 2009).
2.2.5. Endocrine changes
The risk of CSCR is higher in case of prior or current pregnancy
(adjusted OR: 7.1; 95% CI, 1.0e50.7) (Haimovici et al., 2004),
particularly during the third semester. It can resolve spontaneously
after delivery (Chumbley and Frank, 1974; Errera et al., 2013;
Schultz et al., 2014), linking cortisol levels and/or pregnancy-
associated hormonal variations to CSCR (Cousins et al., 1983;Author and publication date
/day (Chaine et al., 2001)
(Koyama et al., 2004)
(Loo et al., 2006)
(Spraul et al., 1998)
(Spraul et al., 1997)
(Tsai et al., 2014)
(Wakakura et al., 1997)
g/day (Gass and Little, 1995)
(Bouzas et al., 1999)
(Bandello et al., 2002)
(Levy et al., 2005)
(Bevis et al., 2005)
ay (Wakakura and Ishikawa, 1984)
mg/day (Bevis et al., 2005)
(Spraul et al., 1998)
mL (Imasawa et al., 2005)
(Kocabora et al., 2008)
amcinolone acetonide
mg Methylprednisolone acetate
(Kao, 1998)
(Iida et al., 2001)
(Pizzimenti and Daniel, 2005)
0 mg/mL) (Baumal et al., 2004)
metasone furoate cream) (Fernandez et al., 2004)
(Karadimas and Bouzas, 2004)
(Romero et al., 2005)
(Ezra et al., 2011)
40e80 mg) (Mondal et al., 2005)
(Hurvitz et al., 2009)
(Kassam et al., 2011)
(Haimovici et al., 1997)
(Kleinberger et al., 2011)
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CSCR develops in up to 5% of patients with endogenous Cushing
syndrome (Bouzas et al., 1993; Carvalho-Recchia et al., 2002). The
relationship between endogenous steroids and CSCR was evaluated
in several comparative studies: the 8-am and 11-pm serum cortisol
levels (Garg et al., 1997; Zakir et al., 2009) and total 24-h urine
cortisol level (Garg et al., 1997; Kapetanios et al., 1998) were
increased in acute CSCR patients as compared to normal subjects. In
an observational series of 24 acute CSCR cases (Haimovici et al.,
2003), 50% of patients had elevated 24-h urine cortisol and tetra-
hydroaldosterone levels, whereas serum aldosterone levels were
low in 29% of patients, indicating that mineralocorticoid regulation
could also intervene in the pathogenesis of CSCR. Twenty-nine
percent of patients exhibited elevated single morning plasma
catecholamine level, but normal 24-h urine metanephrines, the
byproducts of catecholamine breakdown. Serum testosterone
levels were not raised in a cohort of CSCR patients compared to
controls (Zakir et al., 2009).
2.2.6. Psychopathology
In 1986, Yannuzzi observed an association between CSCR and
“type-A” personality pattern, characterized by a competitive drive,
a sense of urgency, an aggressive nature and a hostile temperament
(Yannuzzi, 1986). Subsequently, anti-psychotropic medication use
and psychological stress were described as independent risk factors
for CSCR (OR: 2.6; 95% CI, 1.30e5.19) (Tittl et al., 1999) and psy-
chiatric illness (depression) was associated with an increased risk
of recurrence (HR: 3.50; 95% CI, 1.33e9.23) (Fok et al., 2011). In a
questionnaire-based study of 31 CSCR cases compared to 31
matched controls, no excess of critical life events (regarding social,
professional, health and ﬁnancial categories) was observed among
CSCR patients, but higher levels of emotional distress, somatization,
depression and hostility were observed (Conrad et al., 2007). More
recently, the possible association between narcissistic personality
(characterized by an extreme gratiﬁcation of self) and CSCR was
suggested (Carlesimo et al., 2014). Indeed, a systematic analysis of
57 CSCR patients and 57 age- and gender-matched controls was
performed using psychometric questionnaires, which evaluate the
emotional distress and psychopathology (i.e., somatization,
obsessive-compulsive disorder, interpersonal sensitivity, depres-
sion, anxiety, hostility, phobic anxiety, paranoid ideation, and
psychoticism) and the personality (based on the Temperament and
Character Inventory). Compared to healthy controls, CSCR patients
presented with signiﬁcant higher emotional distress index in all
psychopathological categories and lower cooperativeness and
reward dependence. Such individuals are hostile, critical, unhelpful,
and opportunistic, have low consideration of other people's rights
or feelings with a tendency to manipulate others for their own gain.
This trait is in line with type-A personality that is associated with
opportunistic competitiveness, aggression, hostility and low
threshold of frustration tolerance. CSCR patients are particularly at
risk of the development of stress-induced vision threat in their
working environment and may have low therapeutic compliance
(Conrad et al., 2014).
2.2.7. Gastroesophageal disorders
Gastroesophageal reﬂux and CSCR share stress and adaptive
response to stress as risk factors. In a retrospective caseecontrol
study, CSCR patients had a higher risk of gastroesophageal reﬂux
(OR: 6.05; 95% CI, 2.14e17.11) and of anti-acid or anti-reﬂux
medication use (OR: 15.00; 95% CI, 1.91e117.58) (Mansuetta et al.,
2004). Interestingly, a recent population-based retrospective
study investigating the risk factors of CSCR in Taiwan identiﬁed
peptic ulcer (adjusted OR: 1.39; 95% CI, 1.14e1.70) and higher
monthly income (adjusted OR: 1.30; 95% CI, 1.08e1.57) asindependent risk factors (Chen et al., 2014). Among CSCR patients,
the risk of peptic ulcer was higher after the diagnosis of CSCR.
Several studies also reported a high prevalence of Helicobacter py-
lori infection in CSCR patients (Ahnoux-Zabsonre et al., 2004;
Cotticelli et al., 2006; Giusti, 2001; Mateo-Montoya and Mauget-
Faÿse, 2014; Mauget-Faÿsse et al., 2002; Roshani et al., 2014).
H. pylori-dependent immune mechanism and molecular mimicry
between pathogenic antigens and host proteins (Giusti, 2004) has
been hypothesized but additional studies are needed to conﬁrm the
relationship between CSCR and H. pylori, and the beneﬁt of H. pylori
treatment on the course of CSCR, as suggested by some studies
(Casella et al., 2012; Dang et al., 2013; Rahbani-Nobar et al., 2011).
2.2.8. Drug-induced CSCR (other than steroids)
CSCR episodes have been associated to the use of sympatho-
mimetic drugs, which can be related to the altered reactivity proﬁle
of CSCR patients to sympathetic stimuli (see 2.2.3). In two separate
case series, CSCR has been linked to the following adrenergic re-
ceptor antagonists: pseudoephedrine and oxymetazoline (con-
tained in nasal sprays prescribed for upper airways congestion),
MMDA (an illicit amphetamine) and ephedra (contained in body-
building dietary products) (Michael et al., 2003; Pierce and Lane,
2009).
CSCR has also been described after the use of
phosphodiesterase-5 inhibitors (sildenaﬁl, tadalaﬁl, vardenaﬁl), but
there is conﬂicting evidence regarding CSCR resolution after
treatment discontinuation (Aliferis et al., 2012; Fraunfelder and
Fraunfelder, 2008).
Up to 65% of patients receiving oral MEK-inhibitors (binimeti-
nib) for metastatic cancer, develop transient bilateral serous retinal
detachments and moderately blurred vision (McCannel et al., 2014;
Urner-Bloch et al., 2014). Clinical manifestations occurred within
days after initiation of MEK-inhibitor therapy and, with a dose-
dependent effect on central retinal thickness on OCT imaging. In
all reports, symptoms and subretinal ﬂuid spontaneously resolved
without treatment interruption. In part of these cases, an associated
anterior uveitis suggests the hypothesis of an inﬂammation-
induced serous detachment. Interestingly, no abnormalities were
found on ﬂuorescein or indocyanine green (ICG) angiography.
2.2.9. Sleep disturbances
The role of sleep disturbances and particularly obstructive sleep
apnea in CSCR is controversial. Obstructive sleep apnea has been
reported in 22% of CSCR patients, which is markedly elevated
compared to 2e4% reported in the general population (Eom et al.,
2012; Kloos et al., 2008). But the retrospective questionnaire-
based analysis of 48 CSCR patients and 48 age-, gender- and body
mass index-matched control subjects revealed a similar rate of
obstructive sleep apnea in CSCR (46%) and controls (44%) (Brodie
et al., 2015). This discrepancy can be explained by neutralization
of the body mass index co-factor, an established risk of obstructive
sleep apnea.
2.3. Clinical presentation: forms and deﬁnitions
The term “CSCR” covers two distinct entities, classically deﬁned
as the acute and chronic forms of the disease. This distinction is
somewhat ambiguous because it relies on a temporal criteria (the
duration of the serous retinal detachment), and on the presence of
extended RPE changes. In the acute form (Figs. 1 and 2), patients
report symptoms related to the localization of the subretinal
detachment (SRD) in the macular area: blurred vision, relative
central scotoma, metamorphopsia, moderate dyschromatopsia,
hypermetropization, micropsia and reduced contrast sensitivity,
which have been already extensively investigated (Wang et al.,
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clinically detectable on fundus examination and on OCT, with
limited focal or multifocal RPE alterations that may be limited to
small pigment epithelial detachments (PEDs), and leakage through
the RPE on ﬂuorescein angiography (FA). The SRD usually resolves
within 3e4 months, leaving in most cases no long-term symptoms,
except color discrimination defects in some patients (Baran et al.,
2005). Possible permanent functional changes were described on
ERGs. The term “classic” CSCR has been also used to describe these
patients with a circumscribed area of subretinal ﬂuid associated
with one or a few leaks seen on FA.
No consensus exists over the duration threshold that differen-
tiates acute and chronic CSCR, arbitrarily set between 4 and 6
months in most published reports. This limit is critical for thera-
peutic studies since it determines the appropriate timing for
intervention, when self-resolution is no longer to be expected.
Authors have referred to acute CSCR with persistent SRD after this
initial period as ”chronic” CSCR. However, we suggest that the
terms “non-resolving” or “persistent” CSCR aremore appropriate to
describe these cases with long-lasting SRD, preventing confusion
with the chronic form characterized by a diffuse pigment
epitheliopathy.
This chronic form (Figs. 3 and 4), which had been initially
termed “diffuse retinal epitheliopathy” and was described as a
variant of CSCR (Yannuzzi et al., 1992) is characterized by wide-
spread tracks of RPE atrophy characterized by their decreased
fundus autoﬂuorescence (FAF) (Imamura et al., 2011; Teke et al.,
2014). Symptoms are permanent with moderate to severe visual
acuity loss and decreased light sensitivity depending on the degree
of photoreceptors outer segments damage (Ooto et al., 2010b;
Piccolino et al., 2005). In addition to chronic SRD, OCT shows
multifocal RPE atrophy in areas corresponding to the hypo-
autoﬂuorescent tracks, and irregular RPE detachments. Intra-
retinal cystoid cavities can also be observed (Iida et al., 2003;
Piccolino et al., 2008a) and are associated with disease duration
longer than 5 years (Piccolino et al., 2008b). Aggressive forms of
chronic CSCR characterized by bullous SRD and massive exudation
with subretinal ﬁbrin deposits have been referred to as “multifocal
posterior pigment epitheliopathy” (Uyama et al., 1999), a term
rarely employed in the recent literature. As detailed in 2.1.3, bullous
serous detachments seem more frequent in the Asian population,
and are exacerbated by systemic corticosteroid treatment, as it
occurs when CSCR is misdiagnosed for an inﬂammatory chorior-
etinal disorder.
A consensual deﬁnition of the various clinical subtypes of CSCR
and their exact limits is critical in the prospect of clinical trial
design. We suggest the following deﬁnitions and indicate the main
issues raised for each entity:
 Acute CSCR: self-resolving SRD within 4 months from the onset
of symptoms. Should we consider it differently if pachychoroid
and/or epitheliopathy are present in the contralateral eye? Or if
signs of previous episodes are present in the diseased eye?
 Non-resolving CSCR (or “persistent” CSCR): acute CSCR with
duration of SRD longer than 4 months after onset of symptoms,
often associated with elongated photoreceptor outer segments
on SD-OCT. Should we consider the existence of a new leaky
point on FA as an exclusion criteria, classifying thus the patient
as recurrent CSCR?
 Recurrent CSCR: episode of acute CSCR following a previous
episode with complete SRD resolution. Should recurrent CSCR
be regarded differently if they originate from the same or from
new leaky point on FA?
 Chronic CSCR (formerly “diffuse retinal epitheliopathy”):
chronic chorioretinopathy with widespread RPEdecompensation with or without SRD, associated or not with
active leakage sites. Should we include in this deﬁnition the
recently introduced “pachychoroid pigment epitheliopathy”
(Warrow et al., 2013), or should it be considered as a separate
entity?
 Inactive CSCR: patients with history of acute CSCR but without
SRD at the time of evaluation
An important point of terminology is the distinction between
non-resolving and chronic CSCR. Whether uncomplicated acute
CSCR can evolve into chronic CSCR with diffuse RPE disease, or
whether they are two different entities, is still debated. Evidence of
this connection relies on illustrative case reports and case series
(Bujarborua, 2001; Katsimpris et al., 2007). In one report, 8 of 50
patients demonstrate three years after initial evaluation a more
extended surface of RPE defects on FA (Castro-Correia et al., 1992).
Noticeably, most reports include cases from ethnic groups in which
CSCR often follows a more aggressive course (African, Indian and
Portuguese patients), as discussed in 2.1.3.
Although disease manifestations are usually reported by pa-
tients in one eye due to the presence of a macular SRD, CSCR pre-
sents often as a bilateral condition. Bilateral involvement has been
reported in up to 40% of cases (G€ackle et al., 1998). In an analysis of
74 cases, 4% presented bilateral CSCR at the time of diagnosis, 8% of
unilateral cases had either a history of CSCR or FA ﬁndings indica-
tive of CSCR in the contralateral eye, and 9% of patients initially
diagnosed with unilateral disease developed CSCR in the other eye
during follow-up (Kitzmann et al., 2008). In a retrospective case
series of 229 patients, 32% of asymptomatic fellow eyes presented
ﬂuorescein angiographic features indicating healed or subclinical
CSCR, including SRD, PEDs, depigmented or atrophic RPE patches,
drusen-like deposits, or pigment clumps (Bujarborua et al., 2005).
2.4. Multimodal imaging of CSCR
The diagnosis and follow-up of CSCR relies mostly on multi-
modal imaging.While SD-OCT is the primarymodality, FAF is useful
to non-invasively identify RPE alterations from previous episodes,
and FA indicates the origin of leakage at baseline. Recurrent, non-
resolving and chronic cases should beneﬁt from comprehensive
multimodal imaging with SD-OCT, FAF, FA and ICG angiography in
order to guide treatment, follow extension and detect neovascular
or polypoidal components.
2.4.1. Spectral-domain optical coherence tomography
SD-OCT is the primary imaging modality for the diagnosis and
follow-up of CSCR. State-of-the-art SD-OCT devices provide quick,
non-invasive and reproducible high-deﬁnition images of the retinal
layers and pathological modiﬁcations occurring in the macular
area, facilitated by eye-tracking and landmark alignment algo-
rithms which correlate serial images. Recently, enhanced-depth
imaging and swept-source technologies have allowed full-depth
visualization of the choroid, improving the morphological anal-
ysis of choroidal vessels and choroidal thickness measurements.
Beyond subretinal ﬂuid and PEDs associated or not to RPE leakage
sites, other changes observed with SD-OCT imaging have given
insight into the pathogenesis of CSCR. A review of the retinal and
choroidal alterations identiﬁed by SD-OCT in CSCR patients is
summarized in Table 2.
2.4.1.1. Choroid. Compared to healthy subjects, increased choroidal
thickness has been reported in both affected (Imamura et al., 2009;
Jirarattanasopa et al., 2012b; Kim et al., 2011; Kuroda et al., 2013;
Yang et al., 2013a) and fellow eyes of CSCR patients (Goktas,
2014; Maruko et al., 2011c; Yang et al., 2013b) (Fig. 5). In addition,
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choroidal thickness than fellow eyes (Goktas, 2014; Maruko et al.,
2011c; Oh et al., 2014; Yang et al., 2013b). The threshold limit of
“normal” choroidal thickness remains to be determined taking into
account correction for axial length, age and circadian rhythm.
Considering cohort studiesmeasurements, 395 mmcould be used as
a sensitive value to diagnose “thick choroid” or “pachychoroid”
(Lehmann et al., 2015). Table 3 summarizes the reported choroidal
thickness measurements in CSCR from the recent literature.
Choroidal thickening can result from focal or diffuse dilatation
of large choroidal vessels (Fig. 5AeF). These dilated vessels are
commonly localized within areas of increased choroidal vascular
permeability on ICG angiography (Jirarattanasopa et al., 2012b;
Kuroda et al., 2013; Maruko et al., 2011c; Razavi et al., 2014; Yang
et al., 2013a). Above these dilated choroidal vessels, the innerTable 2
SD-OCT ﬁndings in CSCR patients.
Site SD-OCT ﬁnding Comments
Choroid Thickened subfoveal choroid
Dilatated choroidal vessels
More common
on ICG angiogra
Thinning of the “inner choroidal layer”
Focal choroidal excavations 2.8e7.8% in all
in chronic CSCR
RPE PED 53e100% in acu
in chronic form
Colocalizes with
Microrip of the RPE or ﬁssure 12%
RPE hypertrophy 31e50% in reso
RPE atrophy More common
degeneration.
Leakage site Elevation of RPE
PED
19e68% in acut
32e71% in acut
Highly reﬂective areas suggesting ﬁbrinous
exudate in the subretinal space
20.3e52% in ac
Sagging or dipping of the posterior retinal layer 13e43% in acut
Serous retinal
detachment
Elongated photoreceptor outer segments 73% in acute CS
More frequentl
deposits are see
Subretinal hyper-reﬂective deposits 65%e82%. Corre
white-yellow m
hyper-autoﬂuo
Increasing with
Correlation wit
Retina layers Intraretinal hyper-reﬂective deposits in the OPL,
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Correlation wit
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RPE ¼ retinal pigment epithelium, PED ¼ pigment epithelium detachment, BCVA ¼ bes
ELM ¼ external limiting membrane, IS/OS ¼ Inner segment/outer segment, AF ¼ autoﬂu
CSCR ¼ central serous chorioretinopathy.choroidal layer, which includes medium and small vessels, is
thinner than in adjacent areas (Yang et al., 2013a) (Fig. 5A). This
could result from primary atrophy of the choriocapillaris or
compression by the enlarged vessels from the outer choroid.
Interestingly, RPE elevations are usually observed at the site of
dilated vessels, possibly indicating a mechanical stress on the RPE
caused by an underlying compression (Fig. 5B). In some patients,
particularly in the contralateral eyes of active CSCR, an extremely
thickened choroid is observed, inside which all vascular layers are
equally visible without speciﬁc vessel enlargements (Fig. 5D). In
chronic cases, large vessel walls harbor a granular hyper-reﬂectivity
suggesting possible changes in vascular wall structure (Fig. 5F).
Hyperﬂective dots on SD-OCT have been described in the neu-
roretina and subretinal space of CSCR eyes (see 2.4.1.3). They can
also be observed in the choroid, mostly in the inner choroidReference
in areas of midphase hyperﬂuorescence
phy.
(Yang et al., 2013a)
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symptom duration.
h lower ﬁnal BCVA.
(Maruko et al., 2011a)
(Kon et al., 2008)
(Spaide and Klancnik, 2005)
(Wang et al., 2005)
(Landa et al., 2013)
CSCR forms.
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(Ahlers et al., 2009)
(Kon et al., 2008)
(Yalcinbayir et al., 2014)
(Iacono et al., 2015)
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t-corrected visual acuity, OPL ¼ outer plexiform layer, ONL ¼ outer nuclear layer,
orescent, FAF ¼ fundus autoﬂuorescence; ICGA ¼ indocyanine green angiography,
Table 3
Subfoveal choroidal thickness in CSCR patients.
Author Number of eyes/CSCR
type
Number of control
eyes (statistical
adjustment/matching)
Country Mean SFCT ± SD (mm) in CSCR
eyes
Mean SFCT ± SD
(mm) in fellow
eyes
Mean SFCT ± SD
(mm) in control
eyes
OCT type
(Carrai et al.,
2015)
40 active CSCR eyes e Italy 478 ± 114 e e Wide-ﬁeld
EDI-OCT
(Hamzah et al.,
2014)
56 eyes:
 21 acute CSCR eyes
 35 chronic CSCR eyes
e Indonesia 336.6 ± 91.6 (acute, EDI-OCT)
332.0 ± 96.7 (acute, SS-OCT)
388.0 ± 103.4 (chronic, EDI-OCT)
392.6 ± 101.3 (chronic, SS-OCT)
e e EDI-OCT
SS-OCT
(Goktas, 2014) 20 acute CSCR eyes 20 (age-matched) Turkey 461.4 ± 101.4 375.3 ± 103.7
(P < 0.001)
287.6 ± 62.5
(P < 0.001)a
EDI-OCT
(Oh et al.,
2014)
52 eyes with unilateral
classic CSCR
e Korea 298.4 ± 58.7 264.4 ± 52.1
(P < 0.001)
e EDI-OCT
(Lehmann et al.,
2013)
29 eyes
23 active CSCR
22 quiescent CSCR
e France 491.5 e e EDI-OCT
(Yang et al.,
2013a)
68 eyes
 35 acute CSCR
 33 chronic CSCR
3233 (from The Beijing
Eye Study
(Wei et al., 2013)3))
China 478 ± 114 e 254 ± 107 EDI-OCT
(Yang et al.,
2013b)
15 eyes with unilateral
CSCR
15 (age, gender, refractive
error matched)
China 455 ± 73 387 ± 94
(P ¼ 0.04)
289 ± 71
(P ¼ 0.005)a
EDI-OCT
(Kuroda et al.,
2013)
35 classic CSCR 35 (age-matched) Japan 475 ± 138 e 372 ± 120
(P < 0.01)
SS-OCT
(Jirarattanasopa
et al., 2012b)
44 eyes
 23 Classic CSCR
 17 Chronic CSCR
 4 MPPE
17 (age-matched) Japan 374.3 ± 92.9 e 248.4 ± 77.4
(P < 0.001)
SS-OCT
(Kim et al.,
2011)
31 eyes:
 26 acute CSCR
 5 chronic CSCR
29 (age, gender, refractive
error adjusted)
Korea 367.81 ± 105.56 e 241.97 ± 66.4
(P < 0.001)
EDI-OCT
(Maruko et al.,
2011c)
66 eyes:
e 39 acute CSCR
e 27 chronic CSCR
177 (age-matched) Japan 414 ± 109 350 ± 116
(P < 0.001)
250 ± 75
(P < 0.001)a
EDI-OCT
(Imamura et al.,
2009)
28 eyes:
 6 classic CSCR
 16 DRPE
30 (age-adjusted) USA 505 ± 114 e 287 ± 76
(P < 0.001)
EDI-OCT
SD ¼ standard deviation, SFCT ¼ Sub foveal choroidal thickness, DRPE ¼ diffuse retinal pigment epitheliopathy, MPPE ¼ multifocal posterior pigment epitheliopathy,
WM ¼ whole macula, EDI ¼ enhanced-depth imaging, SS ¼ swept-source, OCT ¼ optical coherence tomography, CSCR ¼ central serous chorioretinopathy.
a Compared to the fellow eye group.
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(Fig. 5H). Thirty-two cases of unilateral CSCR with non-resolving
subretinal ﬂuid for more than 4 months were reviewed internally,
revealing choroidal hyper-reﬂective dots in 72% of CSCR eyes versus
29% of unaffected eyes (p ¼ 0.001, Fisher exact test). Hyper-
reﬂective choroidal vessel walls were observed in 84% of CSCR
eyes versus 16% of unaffected eyes (p ¼ 0.001, Fisher exact test)
(unpublished data). This limited observation suggests that beside
increased thickness, other qualitative changes in the choroid may
indicate an active process. Their signiﬁcance and prognosis value
remain to be prospectively analyzed.
Whether the choroid is thicker in chronic than in acute CSCR is
unclear, according to the available literature (Hamzah et al., 2014;
Jirarattanasopa et al., 2012b). The discrepancy between reports is
due in part to the inconsistency of the deﬁnition of chronic CSCR, as
discussed in 2.3.1. A decrease in choroidal thickness has been re-
ported following CSCR resolution, or after physical or medical
treatments (Table 4). However, a decrease in large dilated vessels
diameter may not be associated with a reduction in choroidal
thickness (Fig. 6A and C), masking treatment effect and questioning
the optimal endpoints for clinical trials.
Whilst increased choroidal thickness is associated with CSCR, it
is not mandatory for its diagnosis as typical cases may not present
with increased thickness (Fig. 2B) (Jirarattanasopa et al., 2012b;
Kuroda et al., 2013). Furthermore, there is limitation to the
comparability of choroidal thickness measurements. Firstly there is
a reduction in choroidal thickness with age, axial length, and
myopic refractive error, and the choroid is also thinner in femalesthan inmales (Fujiwara et al., 2009; Ikuno et al., 2010; Li et al., 2011;
Margolis and Spaide, 2009). Secondly, despite recent advances in
automated delineation methods, the repeatability of measure-
ments remains questionable. In all available devices the segmen-
tation of the choroidal boundaries is manual and subject to large
intra-observer variability (Mrejen and Spaide, 2013), especially in
CSCR where increased choroidal thickness further reduces the
reﬂectivity change at the interface between the outer choroid and
the sclera (Kim et al., 2013). In CSCR, the reported intra-observer
and inter-observer differences in choroidal thickness measure-
ments were 32e38 mm and 46e57 mm, compared to 19e25 mm and
26e35 mm in normal eyes, respectively (Kim et al., 2013). These
limitations should be considered when reporting variations of
choroidal thickness after therapeutic intervention.
2.4.1.2. RPE. PED is encountered in 53%e100% of CSCR-affected
eyes (Ahlers et al., 2009; Mitarai et al., 2006; Van Velthoven
et al., 2005; Yang et al., 2013a) (Fig. 6). PED is more frequently re-
ported in chronic CSCR, and is observed inside or outside the sub-
retinal ﬂuid area (Van Velthoven et al., 2005). In addition, PEDsmay
co-localize with areas of dilated, large choroidal vessels and
thickened choroid on SD-OCT, and with vascular hyperpermeability
on ICG angiography (Hirami et al., 2007; Yang et al., 2013a), sug-
gesting that PED may result from choroidal ﬂow deregulation. In
active CSCR cases, combination of SD-OCT with FA identiﬁed an
elevation of the RPE or a PED at the leakage sites (Fig. 6G) in most
(Fujimoto et al., 2008; Kim et al., 2012; Mitarai et al., 2006) or all
cases (Shinojima et al., 2010) from reported series.
Table 4
Decrease in choroidal thickness after treatment or spontaneous resolution.
Author Treatment No. of
eyes
CSCR type Mean SFCT at
baseline ±SD
(mm)
Mean SFCT after
treatment ±SD (mm)
(time from treatment)
SFCT
variation
(%)
P-value OCT type
(Pitcher et al., 2015) Intravitreal aﬂibercept
2.0 mg (4 or 6 injections)
12 Chronic > 3 months 307 ± 72 263 ± 63 (6 months) 12.7 0.0003 EDI-OCT
(Hua et al., 2014) 1/2-ﬂuence PDT 36 Chronic 470 364 (2e3 weeks)
381 (2e3 months)
22.5
18.9
<0.0001 EDI-OCT
(Dang et al., 2014) 1/3-dose PDT 62 Acute 422 ± 132 362 ± 113 (1 month)
339 ± 135 (3 months)
14.2
19.7
<0.001 EDI-OCT
(Alkin et al., 2014) 1/2-ﬂuence PDT 32 Chronic > 6 months 517 ± 98 462 ± 124 (1 month)
457 ± 123 (2 months)
10.6
11.6
0.003 EDI-OCT
(Razavi et al., 2014) 1/2-ﬂuence PDT 12 Acute > 1 month 421 ± 108 380 ± 113 (1 week)
362 ± 111 (1 month)
9.6
13.8
0.005
0.002
SS-OCT
(Brandl et al., 2014) Oral acetazolamide
(125 mg tid, 3 month)
11 <6 months 421 ± 72 360 ± 65 (3 months) 14.5 0.0002 EDI-OCT
Oral acetazolamide
(125 mg tid, 3 month)
9 Fellow healthy eyes 308 ± 67 287 ± 57 (3 months) 6.8 NS
(Kang and Kim, 2013) Spontaneous resolution 16 Acute 459 ± 78 419 ± 54 (NA) 8.7 0.015 EDI-OCT
Low-ﬂuence PDT 20 Chronic > 3 months 416 ± 74 350 ± 89 (1 month) 13.7 0.001
(Uetani et al., 2012) 1/2-dose PDT 10 Chronic > 3 months 387 ± 24 374 ± 23 (4 days)
324 ± 25 (1 month)
325 ± 25 (3 months)
3.2
16.6
16.4
NS
0.005
0.005
EDI-OCT
1/3-dose PDT 6 Chronic > 3 months 351 ± 17 345 ± 20 (4 days)
343 ± 25 (1 month)
355 ± 22 (3 months)
1.9
2.7
2.0
NS
NS
NS
(Maruko et al., 2011b) 1/2-dose PDT 13 Chronic > 6 months 397 ± 108 441 ± 120 (2 days)
323 ± 120 (1 month)
312 ± 117 (3 months)
317 ± 117 (6 months)
321 ± 122 (12 months)
þ11.1
18.7
21.4
20.1
19.1
<0.01
<0.01
<0.01
<0.01
<0.01
EDI-OCT
(Pryds and Larsen, 2012) 1/2-light PDT 16 “Classic” > 3e4 months 421 346 (1 month) 17.8 0.0001 EDI-OCT
(Maruko et al., 2010) Laser photocoagulation 12 Acute 345 ± 127 349 ± 124 (1week)
340 ± 124 (1 month)
þ1.2
1.4
NS
NS
EDI-OCT
1/2-dose PDT 8 Chronic
>6 months
389 ± 106 462 ± 124 (2 days)
360 ± 100 (1 week)
330 ± 103 (1 month)
þ18.8
7.5
15.2
0.008
0.001
<0.001
EDI-OCT ¼ enhanced depth imaging optical coherence tomography, SFCT ¼ subfoveal Choroidal Thickness, SS-OCT ¼ swept-source optical coherence tomography,
PDT ¼ photodynamic therapy, CSCR ¼ central serous chorioretinopathy, LP ¼ laser photocoagulation, 1/2-ﬂuence ¼ 25 J/cm2, 6 mg/m2, 83 s, 689 nm, 1/2-dose ¼ 50 J/cm2,
3 mg/m2, 83 s, 689 nm, 1/3-dose ¼ 50 J/cm2, 2 mg/m2, 83 s, 689 nm, low-ﬂuence ¼ 30 J/cm2, 6 mg/m2, 50 s, 689 nm, 1/2-light ¼ 50 J/cm2, 3 mg/m2, 42 s, 689 nm.
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involved in CSCR progression: mechanical stress resulting from
increased intra-choroidal pressure or dilated choroidal vessels,
reduced RPE adhesion, alteration of hydro-ionic RPE regulation, and
RPE atrophy secondary to choriocapillaris hypoperfusion.
Different types of PED have been described. Whether they result
from different mechanisms has not been characterized. Dome-
shaped PEDs have a sharply demarcated and protruding appear-
ance, and lack signs of RPE hyperplasia (Fig. 6AeD); en face OCT has
been used to assess their morphology and revealed a homogenous
hyporeﬂective circular area with an hyper-reﬂective border (Ahlers
et al., 2009; Van Velthoven et al., 2005). Voluminous dome-shaped
PEDs can develop (Fig. 6C), and exceptionally rupture through the
neurosensory retina into the vitreous cavity, as observed in an
Asian patient (Fig. 6J). This suggests a sustained elevation of the
hydrostatic pressure occurring underneath the detached RPE.
Irregular or wavy ﬂat PEDs (Fig. 6FeH) have also been described.
Irregular PEDs with hyper-reﬂective content overlying an intact
thin hyper-reﬂective layer (attributed to the Bruch membrane),
creating a “double layer sign” are more frequently observed in
chronic CSCR (Shin and Lee, 2012; Yang et al., 2013a) (Fig. 6H).
Irregular PEDs could result from a loss of elasticity of the adjacent
RPE basement membrane, due to chronically elevated RPE. We also
have observed shallow PEDs in chronic CSCR cases, as shown in
Fig. 6E, suggesting that adhesion of the RPEmight be altered in such
cases. The exact site of cleavage has not been ascertained by any
histologic analysis of a CSCR eye but it seems that the RPE and its
own basal membrane (the most inner layer of Bruch membrane)detach from the other layers of Bruch membrane, which remain
attached to the choriocapillaris basal membrane. Abnormal ion and
water transport through the RPE could contribute to the formation
of a ﬂuid pocket on the basolateral side of the RPE, favoring its
subsequent detachment. The mechanisms of RPE reattachment are
not well understood, and PED can ﬂuctuate independently from the
subretinal ﬂuid. With time, the content of a PED could change and
the residual protein content could contribute to the formation of a
thicker RPE band as observed on SD-OCTs of long-standing cases.
As mentioned, the formation of PEDs seems to be tightly asso-
ciated with choroidopathy since PEDs co-localize frequently with
areas of choroidal vascular anomalies on SD-OCT and ICG. Recently,
a study evaluating 15 eyes by swept-source en face OCT found RPE
changes overlying areas of choroidal vascular dilatation in all eyes,
further supporting the correlation between epitheliopathy and
choroidopathy. Interestingly, these dilatations were mostly focal
within the choriocapillaris, equally focal and diffuse at the level of
Sattler's layer and mostly diffuse at the level of Haller's layer
(Ferrara et al., 2014).
Whether epitheliopathy and choroidopathy both result from a
common pathogenic factor or whether the abnormal choroid in-
duces secondary epitheliopathy that in turn permits ﬂuid passage
into the subretinal space remains uncertain. In advanced CSCR
cases (also termed “diffuse retinal pigment epitheliopathy”), large
areas of RPE alterations and detached RPE may not be systemati-
cally associated with subretinal ﬂuid (Fig. 6F). In a series of 38 eyes,
one third of patients with either active or inactive CSCR had mul-
tiple small PEDs located both within and outside the area of serous
Fig. 6. Spectrum of retinal pigment epithelium detachment in central serous chorioretinopathy on SD-OCT. (A) Acute CSCR, two months after regression of symptoms, with a small
and localized dome-shaped pigment ephithelial detachment (PED) persisting despite the resolution of subretinal ﬂuid. (B) Double dome-shaped PED and otherwise healthy RPE
inside a subretinal detachment area. (C) Protruding subfoveal dome-shaped PED despite resolution of subretinal ﬂuid, producing foveal tilting and metamorphopsia. (D) Residual
subfoveal dome-shaped PED overlying a pachychoroid. (E) Shallow PED with hyporeﬂective content in a patient with active CSCR. (F) Extended wavy ﬂat PED with hyper-reﬂective
content overlying a pachychoroid with dilated vessels; granular hypo-autoﬂuorescence corresponding to this diffuse epitheliopathy. (G) Flat PED at the level of a leakage site (arrow,
evidenced on the ﬂuorescein angiogram) in active CSCR. Visible hyper-reﬂective ﬁbrin/protein ﬂow related to the leak. (H) Irregular or wavy ﬂat PED with hyper-reﬂective content
overlying a continuous thin hyper-reﬂective layer, realizing a “double layer sign”. (I) Chronic CSCR with typical hypo-autoﬂuorescent gravitational tracks (evidenced on fundus
autoﬂuorescence), intraretinal cystoid degeneration and intraretinal hyper-reﬂective dots. There is a diffuse pigment epitheliopathy, with areas of RPE hyperplasia (arrow) and RPE
atrophy (star). (J) Spontaneously ruptured PED in a CSCR patient from India, with resulting full-thickness retinal defect and expulsion of hyper-reﬂective material in the vitreous
cavity, suggesting that the hydrostatic pressure was elevated inside the PED.
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(Van Velthoven et al., 2005). The difference between “simple” acute
CSCR and chronic cases relies mainly on the extension of RPE
involvement. Besides PEDs, focal RPE rips, areas of RPE atrophy and
RPE hypertrophy have been described, and may belong to a wider
spectrum of localized and diffuse epitheliopathy involved in the
different stages of CSCR (Lim and Wong, 2008; Piccolino et al.,
2008a; Yalcinbayir et al., 2014; Yang et al., 2013a) (Fig. 6I). With
time, the chronic course of the disease associated with aging leads
to widespread RPE atrophy and irregular PEDs. Exclusion of a
neovascular component can be challenging at this advanced stages.
Interestingly, drusen are typically not observed in CSCR eyes, sug-
gesting that epitheliopathy in CSCR and AMD originates from
different mechanisms, even if late complications may be similar.
2.4.1.3. Neurosensory retina. One of the characteristics of acute
CSCR is that despite subretinal ﬂuid, the morphology of retinal
layers remains unchanged, except for the elongation of photore-
ceptor outer segments. No reduction or ﬂuid accumulation is
observed in neuronal layers. However after several years of disease
duration, intraretinal cysts can form (Fig. 6I). Theymay disappear or
ﬂuctuate, suggesting ﬂuid passage through a compromised RPE
contribute to their formation. Interestingly, in the inter-
papilomacular region, intraretinal cysts are often observed earlier
in the disease evolution, over areas of RPE atrophy (Iida et al., 2003;
Piccolino et al., 2008a, 2008b). Hyper-reﬂective dots frequentlyaccumulate in the subretinal space below the detached neurosen-
sory retina (Kon et al., 2008; Maruko et al., 2011a; Spaide and
Klancnik, 2005) and within several retinal layers (Ahlers et al.,
2009; Kon et al., 2008; Yalcinbayir et al., 2014). These dots, iden-
tiﬁed on SD-OCT, co-localize with hyper-autoﬂuorescent area on
FAF (Iacono et al., 2015; Maruko et al., 2011a; Spaide and Klancnik,
2005). As disease persists over time, the number of dots located in
the subretinal space tends to increase (Wang et al., 2005) and
correlates with worse ﬁnal visual acuity (Landa et al., 2013, p. 201;
Yalcinbayir et al., 2014). The origin and nature of these dots may be
multiple depending on their size and location. In the subretinal
space, macrophages and microglia are likely to be activated by the
photoreceptor outer segments shedding (Maruko et al., 2011a).
Concentration of protein-like compounds, ﬁbrin or lipids could also
be identiﬁed as dots (Kon et al., 2008). During acute CSCR evolution,
the intraretinal hyper-reﬂective dots progress from the inner to the
outer retinal layers and slowly resolve upon resolution of SRD
(Plateroti et al., 2014). Chronic and recurrent forms of CSCR are
more frequently associated with intraretinal hyper-reﬂective dots
(Ojima et al., 2007).
Elongation of photoreceptor outer segments in the area of a
macular SRD is a frequent SD-OCT ﬁnding in CSCR (Matsumoto
et al., 2008). They are more frequent when white-yellowish pre-
cipitates are observed on fundus examination, corresponding to
patchy increased autoﬂuorescence (Fig. 7) (Matsumoto et al., 2011).
Just above the leaking point, an erosion of photoreceptor outer
Fig. 7. Progressive elongation of photoreceptor outer segments in acute central serous chorioretinopathy. Acute CSCR in a 61 year-old female patient. SD-OCT at baseline, 1, 2 and 4
months (B, D, F, H, respectively) shows progressive elongation of photoreceptor outer segments over the course of CSCR resolution. Fundus autoﬂuorescence initially showed a
decreased autoﬂuorescence (dots) due to the RPE masking by these elongated outer segments (A), which progressively faded due to the accumulation of autoﬂuorescent byproducts
in these segments (C, E), and ﬁnally left a granular hyper-autoﬂuorescence after episode resolution (G, arrow). This hyper-autoﬂuorescence may originate from outer segments
disruption (H, within dotted lines) creating a window defect.
A. Daruich et al. / Progress in Retinal and Eye Research 48 (2015) 82e118 95segments may be visible on SD-OCT, suggesting a mechanical
abrasion resulting from an active ﬂow through the RPE break
(Fig. 2A). Persistent thick outer segments may progress to perma-
nent subretinal deposits with subsequent poor visual prognosis
after subretinal ﬂuid absorption. Complete disappearance of outer
segments as observed in very long-standing SRD correlates with
poor visual outcome. Disruption of the ellipsoid zone (formerly
known as the junction between the inner and outer segments of
photoreceptors), of the external limitingmembrane and thinning of
the outer nuclear layer are also negative visual prognosis factors
(Eandi et al., 2005; Matsumoto et al., 2009, 2008; Ojima et al., 2007;
Piccolino et al., 2005; Yalcinbayir et al., 2014). These ﬁndings are
consistent with recent observations on adaptive optics scanning
laser ophthalmoscopy (see 2.4.5).
2.4.2. Fundus autoﬂuorescence
Short-wavelength FAF mostly originates from the RPE lipofuscin
(Delori et al., 1995). Images obtained by confocal FAF provideinformation reﬂecting RPE health and allow a non-invasive detec-
tion of a spectrum of changes at different phases and forms of CSCR.
Focal areas of hypo-autoﬂuorescence at the level of the leakage
points are indeed observed in 70e100% of eyes with acute CSCR
(Fig. 2D), which supports the hypothesis of a focal RPE defect or
detachment of RPE cells at this site (Ayata et al., 2009; Eandi et al.,
2005; Iacono et al., 2015; Kim et al., 2013). In recurrent CSCR, the
leakage point is usually different from previous episodes but lo-
cates in the vicinity of the ﬁrst one, reﬂecting a barrier weakness
persisting in this area.
In acute CSCR cases, a diminished FAF is initially seen in an area
corresponding to the SRD. It may either return to normal, as
observed in a majority of cases after SRD resolution (Iacono et al.,
2015), or be progressively replaced by an increased FAF, as
observed in episodes persistingmore than 4months (Framme et al.,
2005). While the masking produced by the SRD and the elongated
photoreceptor outer segments could explain the initial decrease in
FAF (Fig. 7), the accumulation of non-shed ﬂuorophores in these
Fig. 8. Indocyanine green angiography anomalies in two cases of acute CSCR. In a ﬁfty-year old man with acute CSCR, focal hypoﬂuorescence during early phase (A) indicated
delayed choriocapillaris ﬁlling (star) and enlarged choroidal veins were visible (arrows). Multifocal hyperﬂuorescence areas with blurred contours indicating choroidal vascular
hyperpermeability (white arrows) appeared during mid phase (B) and faded at late phase (C). A hyperﬂuorescent punctate spot (yellow arrow) during mid- and late phase cor-
responded to the leakage point on ﬂuorescein angiography (not shown). In a thirty-two year-old male with acute CSCR, there was multifocal hyperpermeability (arrows) visible
during mid phase indocyanine green angiography (D), with a progressive circular extension (E) and fading during the late phase (F). Again, two punctate spots (yellow arrow) with
persisting focal hyperﬂuorescence corresponded to leakage points on the ﬂuorescein angiogram (not shown).
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increased patchy FAF in the SRD area of non-resolving cases
(Matsumoto et al., 2011). In addition, a residual granular increased
FAF may remain visible after resolution and correlates with intra-
retinal hyper-reﬂective dots on SD-OCT (Iacono et al., 2015). It has
been recently proposed that this residual granular hyper-Fig. 9. Related entities and differential diagnosis of central serous chorioretinopathy. Polyp
hyperpermeability on indocyanine green angiography (A), and a subretinal detachment over
OCT (B). Choroidal hemangioma manifesting with a serous retinal detachment (C), suspecte
by indocyanine green angiography with progressive hyperﬂuorescence (E) and late wash-oautoﬂuorescence after CSCR resolution could originate from a loss
of photoreceptor outer segments. Indeed, these outer segments are
densely ﬁlled by photopigments (opsins in cones and rhodopsin in
rods), which absorb the blue light and block partially the RPE
autoﬂuorescence in healthy conditions (Freund et al., 2013)
(Figs. 4A, H and 7G, H). Finally, in two separate case series involvingoidal choroidal vasculopathy with multifocal nodular hyperﬂuorescence and choroidal
lying a pigment epithelial detachment with polypoidal hyper-reﬂective content on SD-
d by the visualization of a sub-RPE mass on oblique SD-OCT sections (D) and conﬁrmed
ut (F). (Images 11 CeF: courtesy of Leonidas Zografos, Lausanne, Switzerland).
Fig. 10. Related entities and differential diagnosis of central serous chorioretinopathy.
Optic disc pit visualized on a fundus photograph (A, arrow) associated with serous
retinal detachment on infrared reﬂectance (B) and SD-OCT (C). Serous retinal
detachment complicating dome-shaped macula in a myopic eye (D). (Images 10AeB:
courtesy of Jean-Antoine Pournaras, Lausanne, Switzerland).
Fig. 11. Mineralocorticoid receptor immunohistochemistry in rat and monkey retina. Immun
mineralocorticoid receptor (MR) is localized in nuclei (dark brown) in the ganglion cell laye
choroidal vascular endothelial cells (B). In the monkey, MR is localized in the same layers (C
the fovea (D). INL ¼ Inner nuclear layer, IPL, inner plexiform layer; ONL, outer nuclear laye
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correlatedwith poor visual acuity (Imamura et al., 2011; Spaide and
Klancnik, 2005), conﬁrming that FAF provides valuable morpho-
logical and functional information regarding RPE health.
In fellow eyes of unilateral cases, previous unnoticed extra-
macular episodes or focal RPE alterations may produce variable FAF
changes, mostly depending on the age of the lesions, with increased
autoﬂuorescence for fresh lesions and decreased autoﬂuorescence
for older lesions, frequently associated with punctate hyper-
autoﬂuorescent spots.
In the chronic forms of CSCR, FAF appearance is pathognomonic
with multiple oblong descending tracks of decreased FAF, often
originating from the optic disc and the macula, that have been
referred to as “gravitational tracks” due to their inferior and vertical
topography. They are surrounded by a thin contour of increased FAF
(Figs. 3 and 6I). The exact signiﬁcance of these lesions is not
elucidated, although it has been suggested that they may result
from chronic movements of residual subretinal ﬂuid (Agarwal,
2012; Framme et al., 2005; Spaide and Klancnik, 2005; von
Rückmann et al., 2002).
Near-infrared autoﬂuorescence is another non-invasive imaging
modality based on the autoﬂuorescence emanating mostly from
choroidal and RPE melanin (Keilhauer and Delori, 2006). Although
not routinely employed in the evaluation of patients with CSCR,
near-infrared FAF is an interesting imaging modality showing in
acute cases an initial autoﬂuorescence decrease. Subsequently it
evolves into complete resolution (Kim et al., 2013), or exhibits a
granular pattern indicating long-term changes in RPE melanin
distribution following a CSCR episode (Ayata et al., 2009; Sekiryu
et al., 2010).
2.4.3. Fluorescein angiography
In acute CSCR, FA usually identiﬁes one or several leakage pointsohistochemistry of MR on parafﬁn rat (A and B) and monkey (CeE) retinal sections. The
r (GCL), the inner nuclear layer (INL) (A), the retinal pigment epithelium (RPE) and the
and E) and is also identiﬁed in cone photoreceptors in the macula (C and inset) and in
r. Bar: A, C and D, 20 mm; B and E, 10 mm.
Fig. 12. Scheme of hypothetic links between CSCR and known effects of MR inappropriate activation in various mineralocorticoid-sensitive organs.
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Although not mandatory for the diagnosis of CSCR, FA is helpful to
conﬁrm the diagnosis and serves as a guide for possible laser
treatment of eccentric leaks (Yannuzzi et al., 2000). Acute cases
usually present with a single leakage site, rarely two or more
(Burumcek et al., 1997). In occurrences where more than one site of
leakage is observed, a single site is usually responsible for the
ongoing episode and can be identiﬁed by FA. In acute CSCR, leakage
sites present most frequently as pinpoints of increasing ﬂuores-
cence along the sequence. They can also follow two classical pat-
terns: the “ink-blot“ pattern, with a progressive expansion of a
circular hyperﬂuorescence arising from a central pinpoint, or the
“smokestack” pattern, in which the hyperﬂuorescence ascends
with a slight lateral diffusion producing a mushroom-like image
above the leaking point. In a study of 479 acute, recurrent and
chronic cases, a smokestack leak was observed in 14% of subjects,
and was predominantly associated with acute early forms, with a
mean of 15 days since onset of symptoms (Bujarborua et al., 2010).
In the mid and late phases, dye pooling into the SRD leads to a
diffuse circular hyperﬂuorescence within the SRD area. PED, a
frequent feature of CSCR, is characterized by early ﬂuorescein
pooling with a resulting hyperﬂuorescence persisting during late
phase.
In chronic forms, diffuse RPE defects provoke multifocal leakage
points visible in mid- and late phases as patches of granularhyperﬂuorescence (Yannuzzi et al., 1984) (Fig. 3B and C).
Finally, sequelae of unnoticed extramacular episodes in affected
or fellow eyes appear as hyperﬂuorescent areas because of
increased transmission through localized RPE atrophy (Fig. 4B and
C).
2.4.4. Indocyanine green angiography
Since its introduction in the early 1990s, digital, and now
confocal ICG angiography has become the gold standard to image
the choroidal vasculature. In CSCR, it provides an insight into
choroidal changes contributing to the disease process, and essential
data to distinguish complex chronic cases from differential entities.
In particular, it helps to identify CNV complicating CSCR (Spaide
et al., 1996a; Yannuzzi, 2011). Patterns observed on ICG angiog-
raphy result from the biochemical properties of indocyanine, a
molecule with twice the molecular weight of ﬂuorescein. Due to its
amphiphilic nature, it possesses afﬁnity for hydrophilic structures
(as certain proteins), lipophilic structures (as LDL- and HDL-
cholesterol) or both (as membrane phospholipids) and stains the
intravascular content, the vascular walls, and extravascular struc-
tures like the choroidal stroma. Moreover, its optical absorption/
emission spectra is shifted towards near-infrared frequencies
compared to the spectrum of ﬂuorescein, which allows the ICG
signal to be better transmitted through the RPE (Desmettre et al.,
2000).
Fig. 13. Aldosterone-induced retinal phenotype. Compared to vehicle-injected eyes (A), aldosterone-injected rat eyes showed retinal glial Müller cells swelling (arrows), increased
choroidal thickness (bidirectional arrow) and dilated choroidal vessels (B). Swelling of retinal pigment epithelial (RPE) cells and focal disruption of the RPE tight junctions (arrow)
are found adjacent to the dilated choroidal vessels (star, C). Increased thickness of RPE apical microvilli can be observed on semi-thin sections (B, stars) and on transmission electron
microscopy (E, arrows) as compared to the vehicle-injected eye (D). INL, inner nuclear layer; IS/OS, inner and outer segments of photoreceptors. Bar: A and B, 20 mm; C, 10 mm; D and
E, 2 mm.
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angiography in CSCR-affected eyes are: (Figs. 3, 4 and 8).
 Early phase: delayed initial ﬁlling of arteries and choriocapillaris
(Prünte, 1995), hypoﬂuorescent areas resulting from decreased
choriocapillaris ﬁlling, and persisting in mid- and late phases
(Kitaya et al., 2003) (Fig. 8A).
 Midphase: dilation of large choroidal veins in areas correlating
to atrophic or elevated RPE on OCT (Hirami et al., 2007),
geographic areas of hyperﬂuorescence with blurred contours
classically interpreted as choroidal vascular hyperpermeability,
one of the hallmarks of CSCR imaging (Piccolino and Borgia,
1994; Spaide et al., 1996b) (Fig. 8B and D).
 Late-phase: the mid-phase hyperﬂuorescent areas evolve into
either persistent hyperﬂuorescence, wash-out or centrifugal
displacement of the hyperﬂuorescence, forming hyper-
ﬂuorescent rings (Tsujikawa et al., 2010) (Fig. 8C, E and F).
The essential role of choroidal hyperpermeability in CSCR
pathogenesis is illustrated by the fact that areas of hyper-
ﬂuorescence in the midphase of ICG angiograms persist after
leakage ceases on FA (Scheider et al., 1993), and recurrence of CSCR
with new leakage develops in areas of persistent midphase ICG
hyperﬂuorescence (Iida et al., 1999).
The areas of PED also exhibit a typical course along the sequence
of ICG angiography:
 Early phase: mild hyperﬂuorescence
 Mid-phase: variable hyperﬂuorescence
 Late phase: marked hypoﬂuorescence surrounded by a possible
hyperﬂuorescent ring, attributed to ICG afﬁnity to ﬁbrindeposits at the margins of the PED (Guyer et al., 1994; Mrejen
et al., 2013). Noticeably, a large PED can appear hyper-
ﬂuorescent if it has an abundant ﬁbrin content stained by ICG, or
a PED overlying an area of hyperpermeability.
In addition, punctate hyperﬂuorescent spots have been detected
duringmid- and late phases in 80e93% of active CSCR. In 61e66% of
eyes they correlated with areas exhibiting one or more of the
choroidal vascular changes listed above on ICG angiography. These
punctate hyperﬂuorescent spots were also observed in unaffected
retinal areas in 55% of affected eyes, and in more than 80% of
contralateral eyes. They were signiﬁcantly associated with
increased choroidal thickness, not only in CSCR, but also in PCV and
to a lesser extent in AMD, and may be a manifestation of the
increased choroidal hyperpermeability and intrachoroidal hydro-
static pressure (Park et al., 2014; Tsujikawa et al., 2010).
On ICG angiography, choroidal changes similar to those of
affected eyes were observed in more than half of asymptomatic
fellow eyes (Iida et al., 1999; Tsujikawa et al., 2010).
2.4.5. Adaptive optics
Adaptive optics scanning laser ophthalmoscopy (AO-SLO) is a
technique allowing in vivo visualization of individual cone photo-
receptors by compensating for the optical aberrations of ocular
media. However, this developing imagingmodality is limited by the
presence of subretinal or intraretinal ﬂuid. In the only published
report to date, it has been used to evaluate the photoreceptor layer
changes in 38 patients with resolved CSCR, compared to 20 normal
subjects (Ooto et al., 2010a). Normal eyes presented a regular
photoreceptor mosaic while CSCR eyes exhibited two distinct pat-
terns: a regular cone mosaic with small dark regions, and an
Fig. 14. Suggested mechanism of mineralocorticoid receptor (MR) activation by mineralo- and glucocorticoids on the choroidal vascular endothelial cell leading to choroidal
vascular dilatation by the up-regulation of KCa2.3 Permanent MR occupancy by glucocorticoids is prevented by the metabolizing enzyme 11-beta hydroxysteroid dehydrogenase
type 2 (11ßHSD2), which transforms the glucocorticoids into metabolites that have a weak afﬁnity for MR. Activation of the MR pathway by either aldosterone or glucocorticoids
induces up-regulation of the endothelial vasodilatory potassium channel KCa2.3 (calcium-dependent channel) that leads to the hyperpolarization of endothelial cells and un-
derlying smooth muscle cells (electric coupling through myo-endothelial gap junctions) resulting in choroid vasodilation. Kþ, potassium; Ca2þ, calcium.
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probably reﬂect severe disturbances of the photoreceptor layer.
Average cone density measured at a distance of 0.2 mm, 0.5 mm
and 1 mm from the fovea was higher in normal eyes than in CSCR
eyes. Among CSCR patients, eyes harboring an irregular cone
mosaic with large dark regions presented lower average cone
density and worse average visual acuity, than these eyes with
regular cone mosaic and small dark regions. In addition, eyes with
disrupted ellipsoid band on SD-OCT had a lower mean cone density
than eyes with intact ellipsoid band, a ﬁnding consistent with the
correlation of outer retinal layers integrity on SD-OCT with favor-
able visual outcome, as described in 2.4.1.3.
2.4.6. Choroidal blood ﬂow
The measure of choroidal blood ﬂow relies on the interaction
between a physical signal (a laser beam) and the movement of red
blood cells in the choroidal vasculature. Choroidal blood ﬂow
changes have been reported in CSCR patients, based on threedifferent devices: laser doppler ﬂowmetry, laser interferometry and
laser speckle ﬂowgraphy (Table 5). On laser doppler ﬂowmetry,
acute CSCR eyes showed a reduction of 45% in foveal choroidal
blood ﬂow compared to healthy fellow eyes. The decreased
choroidal blood ﬂow might be correlated with the localized, non-
perfused areas of the choriocapillaris frequently seen during ICG
angiography (Kitaya et al., 2003). However, using a laser interfer-
ometry, the foveal fundus pulsation amplitude was signiﬁcantly
higher in CSCR eyes that in control eyes, suggesting choroidal
hyperperfusion in CSCR patients (Tittl et al., 2003). The wavelength
used in laser doppler ﬂowmetry is shorter than in laser interfer-
ometry, which allows for the detection of red blood cells in the
choriocapillaris rather than in the deeper large choroidal vessels.
Therefore, these results might reﬂect the variability of the blood
ﬂow in the different layers of the choroid. Interestingly, macular
mean blur rate, an indicator of relative blood ﬂow velocity,
decreased with the regression of CSCR activity; this decrease was
inversely correlated with BCVA recovery (Saito et al., 2013).
Fig. 15. Choroidal phenotype of double transgenic (DT) veCadhMR mice. (AeC) Pigmented mice strain. (DeF) Albinos mice strain. In both strains, the human mineralocorticoid
receptor (hMR) is speciﬁcally over expressed in the vascular endothelium (ve Cadherin promotor). Compared to wild-type (WT, A and D), the double transgenic (DT) mice present
choroidal thickening (bidirectional arrow) and choroidal vessel dilation (B, C, E and F). Disruption of tight junctions (arrows) between the retinal pigment epithelial (RPE) cells (B,
inset and C) and RPE detachment (asterisk in E, inset and F) are associated with choroidal vasculopathy in DT mice. Bar: 25 mm.
Fig. 16. Non-resolving recurrent central serous chorioretinopathy treated by mineralocorticoid-receptor antagonist. Thirty-nine-year old patient treated by oral eplerenone (25 mg
daily) for recurrent CSCR without improvement after 2-month observation. Enhanced-depth imaging OCT at baseline (A) shows subretinal detachment, and pachychoroid (665 mm).
A decrease in subretinal ﬂuid was observed 4 and 5 weeks after initiation of treatment (B and C, respectively), with a parallel decrease in subfoveal choroidal thickness (638 mm and
623 mm, respectively).
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Fig. 17. Non-resolving central serous chorioretinopathy treated by mineralocorticoid-receptor antagonist. Fifty-year old patient treated by oral eplerenone (25 mg daily) for
persistent CSCR with non-resolving subretinal ﬂuid. Enhanced-depth imaging OCT showed a stationary subretinal detachment during a 4-month observation period (A and B). A
decrease in subretinal ﬂuid was observed 2 months after initiation of treatment (C). At the level of the subretinal detachment, the choroidal vascular dilatation decreased, as shown
in the outlined vessel (white dotted line, inset) with a vascular surface change from 0.08 mm2 at baseline to 0.05 mm2 after resolution.
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been reported. Isometric exercise induced a more signiﬁcant in-
crease in choroidal blood ﬂow in patients with chronic, inactive
CSCR than in healthy patients, suggesting an inadequate vasocon-
strictor response in CSCR patients (Tittl et al., 2005).
2.5. CSCR related entities and differential diagnosis
Table 6 recapitulates the most relevant entities that could be
misdiagnosed as CSCR, and presents the clinical and imaging fea-
tures that differentiate them from acute or chronic CSCR.Table 5
Reported methods of choroidal blood ﬂow assessment.
Author Type of Laser Parameters No. of CSCR
patients
CSCR type
(Kitaya et al.,
2003)
Laser Doppler Flowmetry
Diode Laser beam ¼ 670 nm
Intensity ¼ 20 mW
Diameter ¼ 200 mm
11 Acute
(Tittl et al.,
2003)
Laser Interferometry
Laser beam ¼ 780 nm
Intensity ¼ 80 mW
Diameter ¼ 20e50 mm
18 Acute
(Tittl et al.,
2005)
Laser Doppler ﬂowmetry
Laser beam ¼ 785 nm
Intensity ¼ 90 mW
Diameter ¼ 50e100 mm
14 Chronic- inactive
(Saito et al.,
2013)
Laser speckle ﬂowgraphy
Diode laser beam ¼ 830 nm
21 Acute
FPA ¼ fundus pulsation amplitude, CBF¼ choroidal blood ﬂow, MBR ¼macular mean blu2.5.1. Polypoidal choroidal vasculopathy (PCV)
PCV (Fig. 9A and B) is considered a variant of CNV as the
branching vascular network originates from the choroidal vascu-
lature. But whether real neovascular proliferation occurs is yet to be
veriﬁed. According to recent guidelines, PCV should be suspected
when a SRD is associatedwith at least one of the following features:
subretinal orange nodules or massive submacular hemorrhage on
fundus examination, serous, sero-sanguineous or notched PEDs on
OCT, or non-response to anti-vascular endothelial growth factor
(VEGF) therapy. PCV is conﬁrmed by ICG angiography, showing
during early-phase an abnormal vascular network with single orNo. of controls (type) Results P value
11 (fellow eyes) The foveal CBF in eyes with CSCR
was 45% lower than in fellow eyes
(6.27 vs 11.41 a.u.)
<0.01
18 (healthy patients) The foveal FPA was higher in eyes
with CSCR that in control eyes
(5.5 mm vs 4.1 mm)
0.005
14 (healthy patients) Isometric exercise induced a more
signiﬁcant increase in CBF in patients
with CSCR than in controls (20% vs 10%)
0.001
e MBR decreased with the course of CSCR
(92.8% of baseline value at 3 month and
82.3% at 6 months)
Inverse correlation between BCVA
improvement and MBR decrease.
0.016
0.000003
r rate, BCVA¼ best-corrected visual acuity, CSCR ¼ central serous chorioretinopathy.
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“polyps” (Koh et al., 2013). Since PCV and CSCR both present with
serous detachments and RPE abnormalities, the distinction be-
tween both entities may be complex. Small polyps may be only
associated with a SRD or non-speciﬁc PEDs, without other exuda-
tive manifestations. On the other hand, advanced CSCR cases may
harbor diffuse blood-retinal barrier disruption, lipid exudates and
even macular hemorrhage when complicated by CNV, possibly
fulﬁlling the criteria of presumed PCV.
The overlap between the two entities has been illustrated in a
series of 13 cases initially diagnosed as CSCR, but inwhich ICG (in 11
cases), or FA (in 2 cases) identiﬁed a polypoidal branching network
leading to a revised diagnosis of PCV (Yannuzzi et al., 2000).
In addition, PCV may share ICG-angiographic features with
CSCR, including choroidal hyperpermeability (Sasahara et al., 2006)
and punctate hyperﬂuorescent spots (Park et al., 2014), which re-
ﬂects the contribution of choroidal changes in PCV pathogenesis.
Increased choroidal thickness in PCV eyes has also been reported in
several case series comparing them to healthy eyes (Kim et al.,
2011; Rishi et al., 2013) and AMD cases (Jirarattanasopa et al.,
2012a; Kim et al., 2011; Koizumi et al., 2011; Rishi et al., 2013). In
one report, choroidal thickness was lower in PCV than CSCR eyes,
although non signiﬁcantly (Kim et al., 2011).
In addition to clinical and angiographic features differentiating
PCV from CSCR, ﬁne tomographic signs related to the more intense
exudation are observed in PCV. In a comparative case series based
on multimodal imaging and speckle noise-reduced SD-OCT, an
enhanced variant of SD-OCT, PCV was more frequently associated
with intraretinal cystoid edema, presence of intraretinal lipid de-
posits, and hemorrhagic PED than CSCR (Ooto et al., 2011). Recently,
Baek and colleagues analyzed by SD-OCT the optical density of
subretinal ﬂuid (relative to the vitreous, the RPE and the retinal
nerve ﬁbers layer), showing that all optical density ratios were
higher among patients with PCV compared to those with acute or
chronic CSC (Baek and Park, 2015).
The link between CSCR and PCV should be further explored. PCV
was found more frequently in Asian patients with a history of CSCR
(Toyama et al., 2014). Whether pachychoroid could predispose to
either CSCR or PCV depending on associated factors such as genetic
background or exogenous factors remains to be determined.
2.5.2. CSCR-associated choroidal neovascularization
Choroidal neovascularization (CNV) can complicate CSCR, with
reported incidence rates ranging from 2%, in a series of 101 eyes
with mean follow-up of 9.8 years (Loo et al., 2002) to 9% in a series
of 130 patients, inwhich 84% of CNV cases occurred in subjects over
50 years of age (Spaide et al., 1996a). Other studies found no as-
sociation, as for instance a series of 340 eyes with a mean follow-up
of 49 months (Mudvari et al., 2007). As occurring in AMD or
pathologic myopia, chronic alterations of Bruchmembrane and RPE
involved in CSCR pathogenesis have been postulated as causative
factors for CNV formation. Until recently, in reports where the
classiﬁcation of CSCR-associated CNVs was addressed, they were
classiﬁed as “Type 2” CNVs (Chan et al., 2003b; Lafaut et al., 1998).
The observation of Type 1-CNV in CSCR is more recent and will be
detailed in 2.5.3. In CSCR patients treated with laser photocoagu-
lation, CNV may occur as a late complication as high-energy spots
can disrupt the RPE (Simon et al., 2001). These cases respond
usually very well to a limited number of anti-VEGF injections, as
discussed in 2.6.3.1.
2.5.3. Type 1 CNV, chronic CSCR and “pachychoroid
neovasculopathy”
Although resulting from different pathogenic mechanisms and
producing distinct clinical presentations, CSCR and neovascularAMD both affect themacula and result from pathologic processes at
the level of the choroidal vasculature and the RPE. In certain cases,
especially middle-aged adults who present exudative processes,
the distinction between both entities is complex because of over-
lapping clinical and imaging features. A form of Type 1 neo-
vascularization related to long-standing CSCR has been recently
described in two subgroups of patients (Fung et al., 2012). On one
hand, features resembling Type 1 CNV lesions developed over the
course of follow-up in 9 patients diagnosed with chronic CSCR. On
the other hand, Type 1 neovascularization was detected in 13 pa-
tients who presented with associated features closer to chronic
CSCR than to AMD. Mean patient age was 61-years old, mean
subfoveal choroidal thickness was 354 mm and midphase hyper-
permeability was observed in all eyes undergoing ICG angiography.
Interestingly, 36% of cases presented polypoidal structures on ICG
angiography or SD-OCT.
More recently, the term “Pachychoroid neovasculopathy” has
been coined to describe Type 1 CNV overlying focal areas of
choroidal thickening on EDI-OCT and choroidal hyperpermeability
on ICG angiography, without a history of acute or chronic CSCR. In a
detailed account of three cases, all harbored polypoidal-like
structures on ICG angiography or SD-OCT (Pang and Freund,
2015). Therefore, long-standing CSCR, Type 1 neovascularization
and PCV have been suggested to belong to a spectrum of conditions
sharing the “pachychoroid” feature. In this spectrum, pachychoroid
neovasculopathy has been postulated as a possible precursor of
PCV.
In patients with CNV unresponsive to anti-VEGF and not pre-
senting other signs of AMD, the diagnosis of CSCR should be
considered particularly if associated with increased choroidal
thickness in both eyes.
2.5.4. Cavitary optic disc anomalies
Optic disc pit (Fig. 10AeC) and typical congenital optic disc
coloboma are focal excavations located in the optic nerve head
virtually creating a communication between the vitreous cavity, the
subretinal space and to a variable extent the subarachnoid space.
Clinically, they provoke chronic or recurrent serous retinal
detachment with variable intraretinal cystoid edema leading in
advanced cases to a schisis-like appearance. Although controver-
sial, their pathogenicity probably relies on dynamic ﬂuctuations in
the gradient between intraocular and intracranial pressures
(Georgalas et al., 2011; Jain and Johnson, 2014). Careful examina-
tion of the papillary anatomy should then be performed in patients
with chronic SRD or intraretinal edema attributed to CSCR to rule
out optic disc cavitaries anomalies. Among the proposed thera-
peutic options, laser photocoagulation alone or pars plana vitrec-
tomy with careful juxtapapillary laser photocoagulation and gas
tamponade have been attempted to create a permanent peri-
papillary scar and avoid recurrences (Jain and Johnson, 2014).
2.5.5. Circumscribed choroidal hemangioma
Circumscribed choroidal hemangioma (Fig. 9CeF) is a benign
tumor of the choroid, characterized by an orange coloration on
fundus appearance. It is frequently located in the paramacular area,
and presents with serous retinal detachment and focal increased
choroidal thickness, and can therefore bemisdiagnosed as CSCR. On
FAF the lesion can appear iso- or hypoﬂuorescent, with granular
hyperﬂuorescence due to overlying orange pigment (Heimann
et al., 2013). FA presents with increasing ﬂuorescence over the
sequence that may mimick RPE alterations observed in long-
standing CSCR cases. However ICG angiography helps to distin-
guish both entities since circumscribed choroidal hemangiomas
show early hyperﬂuorescence followed by a classical “wash-out
phenomenon” during mid- and late phases (Shields et al., 2001).
Table 6
CSCR related entities and differential diagnosis.
Acute CSCR Chronic CSCR Polypoidal choroidal
vasculopathy
CNV complicating
CSCR
Pachychoroid neovasculopathy
(Type 1 CNV þ pachychoroid)
Dome-shaped macula
with subfoveal
detachment
Optic disc pit Circumscribed
choroidal
hemangioma
Gender M > F M ¼ F F > M (Caucasian)
M > F (Asian)
M > F ? F > M M ¼ F M > F
Age (y) 30e60 40e80 50e65 >50 55e65 20e85 5e90 5e80
Context Personality pattern,
stress, glucocorticoids
Personality pattern,
stress, glucocorticoids
Frequent in Asian men CSCR history Misdiagnosed as early AMD,
resistance to anti-VEGF
Myopia, ﬂuctuating
vision loss
Congenital,
sporadic,
ﬂuctuating
vision loss
Misdiagnosed
as melanoma,
CSCR etc
Fundus SRD, grayish leakage
site
Pigment clumps, RPE
atrophy, subretinal
exudates,
Orange nodules,
hemorrhage
Possible hemorrhage,
lipid exudates
Absence of drusen, reduced
fundus tessellation
Posterior
staphyloma
Optic disc defect,
grayish aspect
Orange-red
elevation
SD-OCT Retina SRD, elongated
photoreceptor outer
segments, hyper-R dots
SRD, cysts, hyper-R
dots
SRD, cysts, lipid
deposits
Features of CSCR þ
non-resolving
outer retinal
exudative signs,
SRD SRD SRD, cysts,
retinoschisis
SRD, cysts
RPE Focal PED(s), subretinal
deposits
Extended/multifocal
PED(s), double layer
sign
PED with hyper-R
heterogenic content,
“Double layer” sign
Feature of chronic
CSCR þ pre-RPE
hyper-R material
Irregular PED, absence of
drusen
RPE elevations,
small PED
Unremarkable RPE thinning
Choroid Dilated outer vessels,
compressed CC
Dilated outer vessels,
compressed CC þ Sattler
Focal or diffuse vessel
dilatation, polyps at
the back of RPE
Dilated outer vessels,
compressed inner
layers
Large choroidal vessels,
compressed CC þ Sattler
Thin with relative
retrofoveal
thickening
Unremarkable Hypo-R lesion
Pachy-choroid Frequent Possible Possible Possible Yes No No Yes
FAF Hypo-FAF (<4 months),
hyper-FAF (>4 months),
pin points
Gravitational tracks
of hypo-FAF
FAF masking by lipids
and blood
e Hyper/hypo-FAF Hypo-FAF
(RPE atrophy)
Hypo-FAF (SRD,
schisis), granular
hyper-FAF
Reduced FAF
over the tumor,
granular
hyper-FAF
FA Early 1e2 leakage points
(pin point, ink-blot,
smokestack), PED:
late hyper-F
Diffuse granular
hyper-F areas,
PED: late hyper-F
Discrete hyper-F CSCR features þ
lacy hyper-F
Discrete hyper-F Pinpoint leakage Hypo-F (pit) Lacy hyper-F
Mid-late Filling of the SRD Diffuse window
defects (RPE atrophy)
Ill-deﬁned hyper-F
(occult leakage)
CSCR features þ
diffusion
(classic CNV)
Ill-deﬁned hyper-F
(occult leakage)
Pinpoint leakage Hyper-F (pit) Increasing
hyper-F,
late leakage
ICG Early Arterial and capillary
ﬁlling delay
Arterial and capillary
ﬁlling delay, PED:
hyper-F
Nodular hyper-F,
branching network
CSCR features þ
variable hyper-F
Nodular hyper-F,
branching network
No Hypo-F (pit) Rapid onset
hyper-F
Mid-late Hyperpermeability,
foci of choriocapillaris
non-perfusion,
punctate hyper-F spots
Hyperpermeability,
enlarged vessels, PED:
hypo-F
Nodular hyper-F,
branching network,
punctate hyper-F
spots, variable
hyperpermeability
CSCR features þ
variable hyper-F
Hyperpermeability,
frequently nodular
hyper-F and branching
network
Punctate spots,
hyperpermeability,
subfoveal hypo-F
Hypo-F (pit) Hypo-F
(“Wash out”),
hyper-F rim
M ¼male; F ¼ female, SD-OCT ¼ spectral-domain optical coherence tomography, ICG ¼ Indocyanine green, FA ¼ ﬂuorescein angiography, FAF ¼ fundus autoﬂuorescence, hyper-R ¼ hyper-reﬂective, hypo-R ¼ hyporeﬂective,
hyper-F ¼ hyperﬂuorescence, hypo-F ¼ hypoﬂuorescence, SRD ¼ serous retinal detachment, CNV ¼ choroidal neovascularization, AMD ¼ age-related macular degeneration, CC ¼ choriocapillaris, RPE ¼ retinal pigment
epithelium, PED ¼ Pigment epithelial detachment.
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caliber of the medium and large choroidal vessels in the tumor,
without choriocapillaris compression (Shields et al., 2014). Photo-
dynamic therapy is a safe and effective treatment for circumscribed
choroidal hemangioma (Gupta et al., 2004).
2.5.6. Dome-shaped macula
Dome-shapedmacula (Fig. 10D) is a forward bulge of the macula
protruding within a posterior pole staphyloma in myopic eyes
(Gaucher et al., 2008). Among reported complications, a ﬂuctuating
serous foveal detachment is observed in approximately 50% of eyes
(Caillaux et al., 2013). It is signiﬁcantly associated with pinpoint
leakage on FA, retrofoveal hypoﬂuorescence with punctate hyper-
ﬂuorescent spots on ICG angiography, small PEDs on SD-OCT and a
greater subfoveal choroidal thickness compared to eyes without
SRD (Viola et al., 2015). These features are very similar to
morphological changes occurring in the choroid of CSCR patients
and may obscure the distinction between both entities, especially
in eyes with small refractive error. This parallel also suggests that
the choroid plays an important role in the pathogenicity of SRDs
complicating dome-shaped macula. SRDs may be spontaneously
resolving (Tamura et al., 2014), but little has been reported
regarding adequate therapy for long-standing cases. A report of two
cases indicated that neither intravitreal bevacizumab nor laser
photocoagulation alone were efﬁcient, whereas SRD resolutionwas
maintained for two years following half-ﬂuence PDT (Chinskey and
Johnson, 2013). On the assumption that mineralocorticoid re-
ceptors may be implicated in the choroidal remodeling associated
with dome-shaped macula, we have reported two cases of chronic
SRD treated with oral spironolactone during 3 and 6 months, with
maintained efﬁcacy until 3 and 12 months, respectively (Dirani
et al., 2014). More investigations are needed to determine the
optimal management of these cases.
In choroidal hemangioma and dome-shaped macula, sclero-
choroidal changes may induce mechanical stress to the RPE,
inducing either alteration of the tight-junctions or changes in their
pumping activity, and leading to subretinal ﬂuid accumulation.
2.6. Treatments
Acute CSCR is a self-limited disease, with re-attachment of the
neurosensory retina occurring within 3e4 months in the majority
of cases (Yannuzzi, 2010). Consequently, observation is the appro-
priate ﬁrst-line approach. Without much controversy in acute
CSCR, such attitude could be discussed in recurrences or in patients
presenting with diffuse epitheliopathy at ﬁrst presentation. Indeed,
long-lasting SRD in recurrent CSCR could increase photoreceptor
damage. Functional studies should be conducted to determine the
consequences of recurrent and chronic macular detachments.
Accurate recurrence rates are difﬁcult to estimate due to the
variability of follow-up durations in the literature. In a series of
reports where follow-up varied from 2 to 13 years, recurrences
were seen in 15e50% of cases. Recurrent or persistent SRD was
identiﬁed as a risk factor of visual acuity worse than 20/40 (Loo
et al., 2002).
There is no consensus about themost suitable treatment and the
optimal timing for intervention in CSCR patients. Classically,
treatment can be justiﬁed in the following indications: persistent
macular SRD for at least 4 months, history of multiple recurrences,
history of CSCR in the fellow eyewith poor visual outcome, reduced
visual acuity, and rapid recovery required (Nicholson et al., 2013).
When CSCR patients present with good visual acuity, the potential
toxicity of treatments, and particularly their delayed toxicity,
should be taken into account in selecting the therapeutic modality.
Physical treatments have been developed to target the RPEleakage, and the vascular choroidal congestion and hyper-
permeability (Chan et al., 2008). Many other medical treatments
have been proposed with few evidence-based results.
2.6.1. Exclusion of risk factors
Interruption of identiﬁed, often occult glucocorticoid treatment
appears beneﬁcial to facilitate the resolution of CSCR episodes
(Polak et al., 1995; Sharma et al., 2004; Wakakura et al., 1997;
Williamson and Nuki, 1970). Proper management of obstructive
sleep apnea could also be discussed. Whether the control of other
identiﬁed risk factors (described in 2.2) would alter the course of
CSCR, especially in chronic cases, has not been reported yet. How-
ever, taking into account the psychopathologic personality proﬁle
of CSCR patients, and their susceptibility to sight-threat-induced
stress, a psychological support associated or not with pharmaco-
therapy should be discussed.
2.6.2. Physical treatments
2.6.2.1. Laser photocoagulation. Green (514 nm) or yellow (580 nm)
laser photocoagulation has been attempted to “seal” the RPE
leakage points. Besides direct thermal sealing effect on the focal
RPE defects, laser is thought to prompt ﬂuid exit (Robertson and
Ilstrup, 1983) and favor expansion of surrounding RPE cells (Lim
et al., 2011). But laser photocoagulation is not expected to act on
choroidal congestion and hyperpermeability (Maruko et al., 2010).
Several studies have compared laser photocoagulation to
observation or sham laser treatment (summarized in Table 7).
Overall, the studies showed that in acute CSCR with obvious focal
leakage on FA, laser photocoagulation hastened the resolution of
neurosensory retinal detachment but did not improve the ﬁnal
visual outcome. In the longest available follow-up studies (6e12
years), it did not reduce the rate of recurrences, which is consistent
with the absence of effect on causative choroidal changes. Although
generally safe, there are few reported adverse effects including
paracentral scotoma and iatrogenic CNV, particularly if performed
in the juxta foveal area (Ficker et al., 1988; Gilbert et al., 1984;
Verma et al., 2004). More recently, subthreshold diode micro-
pulse laser (810 nm) was proposed for the treatment of CSCR
(Behnia et al., 2013; Chen et al., 2008; Koss et al., 2012; Lanzetta
et al., 2008; Roisman et al., 2013). The higher wavelengths would
allow a better choroidal penetration while sparing the inner retina
from the laser injury (Brancato et al., 1989). In a prospective study,
30 CSCR cases with a single leak on FA, at least 300 mm away from
the fovea, were randomized to receive either argon green laser or
subthereshold diode micropulse laser photocoagulation. Sub-
threshold diode micropulse laser was superior to argon green laser
in terms of faster visual recovery and better contrast sensitivity
(Verma et al., 2004). Larger studies should conﬁrm these pre-
liminary ﬁndings.
To date, laser photocoagulation remains an option in acute CSCR
patients with SRD persisting for more than 4 months and a clear
leak on FA, located more than 500 mm away from the fovea.
2.6.2.2. Verteporﬁn photodynamic therapy (PDT). Upon light stim-
ulation at 693 nm and in the presence of oxygen, Verteporﬁn
(Visudyne®; Novartis, Switzerland) releases free radicals in the
choroidal circulation, leading to endothelial vascular damage and
vessel occlusion. PDT with verteporﬁn has been proposed in the
treatment of CSCR based on the assumption that it provoked short-
term choriocapillaris hypoperfusion and long-term choroidal
vascular remodeling, thus reducing choroidal congestion, vascular
hyperpermeability, and extravascular leakage (Chan et al., 2003a;
Schl€otzer-Schrehardt et al., 2002). Among 39 patients treated by
PDT, ICG angiography showed resolution of choroidal vascular
hyperpermeability and reduction in choroidal extravascular
Table 7
Controlled studies reporting the effect of laser photocoagulation on episode duration, best-corrected visual acuity and rate of recurrence.
Author Laser type No. of eyes
(treated/
control)
Randomization Shorter episode
duration in
laser group
(P value)
Mean episode
duration in
laser group
(weeks)
Mean episode
duration in
control group
(weeks)
Type of
control
Better ﬁnal
VA in laser
group
(P value)
Decreased
recurrence
rate in laser
group
(P value)
Follow-up
duration
(months)
(Leaver and
Williams, 1979)
Argon 67 (NA) Yes Yes (P < 0.01) 6 16 Observation No NA 6
(Robertson and
Ilstrup, 1983)
Argon 12 (7/5) No Yes (P ¼ 0.012) 6 15 Laser impact
remote from
leakage site
No Yes
(P ¼ 0.045)
18
(Gilbert et al.,
1984)
Argon 73 (26/47) No NA NA NA Observation No No 58
(Brancato et al.,
1987)
Argon 87 (37/50) No NA 8 12 Observation NA No 96
(Ficker et al.,
1988)
Argon 44 (25/19) Yes NA NA NA Observation No No 108
(Burumcek et al.,
1997)
Argon and
yellow
45 (29/16) No Yes (P > 0.0001) NAa NAa Observation NA Yes
(P ¼ 0.0003)
58
a Data not provided (survival analysis).
A. Daruich et al. / Progress in Retinal and Eye Research 48 (2015) 82e118106leakage at 3 months in 94% of cases, compared to 15% in a group of
19 control subjects receiving saline instead of verteporﬁn (Chan
et al., 2008). Following PDT, a reduction in choroidal thickness of
9e19% at 1 month and 12e21% at 3 months has also been reported
(Table 4).
For CNV, verteporﬁn is approved at a dose of 6 mg/m2 with a
laser ﬂuence of 50 J/cm2. Long-term complications of PDT include
choriocapillaris non-perfusion (44%), secondary CNV (5%) (Reibaldi
et al., 2010), RPE atrophy (4%) and subsequent visual loss (1.5%)
(Lim et al., 2014). Such complication rates are not acceptable for
CSCR patients who still maintain good visual acuity levels. More-
over, severe complications (such as abrupt and profound visual
loss) were reported in CSCR patients after PDT treatment according
to AMD guidelines parameters, leading to reconsider PDT param-
eters for CSCR. Lower-ﬂuence PDT (25 J/cm2) showed that 91% of
eyes had resolution of SRD at 12 months and did not cause cho-
riocapillaris non-perfusion (Reibaldi et al., 2010). Half-dose PDT
(3 mg/m2) showed similar efﬁcacy at 12 months (Chan et al., 2008),
without reported adverse events (Senturk et al., 2011), although it
has not been compared to full-dose PDT. Interestingly,1/3-dose PDT
(2 mg/m2) was less effective than half-dose PDT in terms of sub-
retinal ﬂuid resolution (Uetani et al., 2012).
A recent meta-analysis (Ma et al., 2014) of nine studies (Bae
et al., 2011; Chan et al., 2008; Lee et al., 2011; Lim et al., 2011;
Maruko et al., 2011b; Reibaldi et al., 2010; Semeraro et al., 2012;
Shin et al., 2011; Wu et al., 2011) including 63 acute CSCR and
256 chronic CSCR, deﬁned by persistent SRD > 3 month, has re-
ported that:
- Half-dose PDT was superior to placebo in terms of BCVA
improvement, central macular thickness reduction and SRD
resolution at 12 month.
- Half-dose PDT was superior to laser photocoagulation in terms
of SRD resolution at 1 month, but no signiﬁcant difference was
observed in BCVA and central macular thickness.
- Half-ﬂuence PDT and standard-ﬂuence PDT were superior to
intravitreal anti-VEGF injections in terms of SRD resolution and
central macular thickness diminution at 3 month, but no dif-
ference was observed in BCVA.
- Half-ﬂuence PDT was as effective as standard-ﬂuence PDT and
could signiﬁcantly decrease the regional choroidal non-
perfusion related to the hypoxic damages caused by PDT.
Whether half-dose PDT or half-ﬂuence PDT is superior for thetreatment of CSCR remains unclear. In a retrospective review of 56
patients (Nicolo et al., 2014) with chronic CSCR treated by half-dose
or half-ﬂuence PDT, half-dose PDT induced a more rapid reab-
sorption of surbetinal ﬂuid with respect to half-ﬂuence PDT (83.9%
versus 100% of eyes at 12 months), with a more lasting effect (15
versus 5 recurrences). No eyes developed RPE atrophy in any group.
However, similar rates of subretinal ﬂuid reabsorption, gain of
BCVA, and central macular thickness decrease were observed with
both modalities of treatment in another retrospective study
including 64 eyes (Alkin et al., 2014).
Remarkably, there are no long-term studies (>12 months)
recording visual function, rate of recurrences, beneﬁt of re-
treatments, and rate of adverse events after single or multiple
PDT treatments. Since long-term data following PDT for other
retinal disorders showed that delayed chorioretinal atrophy and
permanent vision loss can be observed, long-term follow-up is
required to assess the safety of PDT in the CSCR patients, who
belong to younger age groups.
2.6.3. Medical treatments
2.6.3.1. Anti-VEGF agents. Although CSCR is not associated with
increased VEGF ocular levels (Lim et al., 2010a; Shin and Lim, 2011),
anti-VEGF therapy was proposed to reduce the choroidal hyper-
permeability (Chung et al., 2013). A limited number of interven-
tional case series reported beneﬁcial effects of bevacizumab in
terms of visual acuity improvement and subretinal ﬂuid reduction
without signiﬁcant complications (Arevalo and Espinoza, 2011;
Artunay et al., 2010; Lim and Kim, 2011; Schaal et al., 2009).
However, the only randomized study comparing ranibizumab to
observation showed no difference in terms of visual acuity, central
retinal thickness or duration of SRD between both groups (Lim
et al., 2010b). More recently, aﬂibercept was used in a pilot study
of 12 patients with persistent ﬂuid over 6 months, showing a
moderate effect on ﬂuid and macular thickness reduction (Pitcher
et al., 2015).
A recent meta-analysis of 4 studies (Artunay et al., 2010; Aydin,
2013; Koss et al., 2012; Lim et al., 2010b) including acute and
chronic CSCR showed that neither visual acuity nor central macular
thickness were signiﬁcantly improved 6 months after intravitreal
bevacizumab, compared to observation, PDT or laser photocoagu-
lation (Chung et al., 2013).
Finally, a few case series indicate a beneﬁcial effect of bev-
acizumab (Chan et al., 2007), ranibizumab (Konstantinidis et al.,
2010) and aﬂibercept (Broadhead and Chang, 2014) on CNV
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To date, the cost/beneﬁt of anti-VEGF is not demonstrated for
CSCR, except for treating clearly identiﬁed CNV.2.6.3.2. Oral treatments. Proper evaluation of a treatment effect
requires a double-blinded, randomized, comparative design using
an adapted placebo. These general concepts are critical for clinical
trials with CSCR patients, given the ﬂuctuating and self-resolutive
nature of CSCR and the particular psychological proﬁle of these
subjects (described in 2.2.6), which may amplify the “placebo
effect”.
Several oral medications have been proposed for the treatment
of CSCR based on the putative inhibition of different pathogenic
pathways. Drugs belonging to the following therapeutic classes
have been evaluated: carbonic anhydrase inhibitorsTable 8
Studies evaluating oral treatments for central serous chorioretinopathy with a control gr
Oral drug (dose) Class, suggested
mechanism
Study design,
control
No. of eyes
(treated/
control)
Follow-up
duration
(months)
F
e
S
Acetazolamide
(500 mg tid,
bid, qd by
2 weeks
periods)
Carbonic anhydrase
inhibitor:
- Acidiﬁcation of the
subretinal space
- Improvement of RPE
polarization and
pump function
- Anti-inﬂammatory
effect
Prospective
non-randomized,
vs observation
22 (15/7) 24 Y
Nadolol
(40 mg qd)
Beta-blocker: inhibition
of sympathetic activity
Randomized,
double-masked,
vs placebo
8 (4/4) 4 N
- Amoxicillin
(500 mg tid
2 weeks)
- Metronidazole
(500 mg tid
2 weeks)
- Omeprazole
(NA,6 weeks)
Antibiotics þ proton
pump inhibitor:
treatment of
Helicobacter pylori
infection
Randomized, vs
observation
50 (25/25) 4 Y
- Amoxicillin
(1 g bid
2 weeks)
- Clarithromycin
(500 mg bid
2 weeks)
- Omeprazole
(20 mg bid,
2 weeks)
Antibiotics þ proton
pump inhibitor:
treatment of
Helicobacter pylori
infection
Randomized,
vs observation
53 (27/26) 3 N
Ketaconazole
(200 mg qd,
4 weeks)
Antifungal, P450
Cytochrome and
11b-hydroxylase
inhibitor: endogeneous
cortisol synthesis
inhibition
Retrospective,
versus
observation
30 (15/15) 1 N
Mifepristone
(200 mg qd,
12 weeks)
Glucocorticoid-receptor
antagonist and
anti-progesterone
Randomized,
double-masked,
vs placebo
8 (4/4) 3 N
Aspirin (100 mg
qd, 1 months;
then every 2
days, 6
months)
Inhibitor of platelet
aggregation:
diminution of
plasminogen activator
inhibitor 1 levels
Prospective
non-randomized,
vs observation
208
(113/95)
18 N
SRD ¼ subretinal detachment, BCVA ¼ best-corrected visual acuity.(acetazolamide), beta-blockers (nadalol, propranolol), antibiotics
(amoxicillin, metronidazole, clarithromycin) and proton pump in-
hibitors (omeprazole) for the treatment of Helicobacter pylori,
imidazoles (ketoconazole), glucocorticoid-receptor antagonists
(mifepristone), anti-platelets (aspirin), antimetabolites (metho-
trexate), 5a-reductase inhibitors (ﬁnasteride), diarylheptanoids
(curcumin), with negative or poor evidence of beneﬁt, as summa-
rized in a recent comprehensive review on CSCR treatments
(Nicholson et al., 2013).
The existing comparative studies evaluating the effect of an oral
medication on the course of CSCR, most of them prospective, are
summarized in Table 8. To date, methotrexate (Kurup et al., 2012),
ﬁnasteride (Forooghian et al., 2011) and curcumin (Mazzolani and
Togni, 2013) have not been evaluated in comparative studies.
Despite relatively encouraging evidence from pilot studies, further
comparative evaluations are then needed.oup.
avorable
ffect on
RD
SRD
evaluation
Better ﬁnal
BCVA in
treated
group
Decreased
recurrence
rate in
treated
group
Comment Authors
es Episode
duration
(3.3 vs 7.7;
p < 0.0001)
No No High rate of
side effects
(Paresthesias,
dyspepsia)
(Pikkel et al.,
2002)
o SRD
resolution
rate
NA No (Browning,
1993)
es Episode
duration
(9.3 vs 11.6;
p ¼ 0.04)
No NA Patients with
positive urease
breath test at
baseline
(Rahbani-Nobar
et al., 2011)
o SRD
resolution
rate
No NA Patients with
positive urease
breath test at
baseline
(Dang et al.,
2013)
o SRD
height
No NA Adverse events:
nausea (1),
erectile
dysfunction (1)
(Golshahi et al.,
2010)
A e NA NA Results non
interpretable
because 4
patients
exited study
before
termination
(Nielsen and
Jampol, 2011)
A e Yes No Tendency in
limitation of
recurrences
but no p-value
provided
(Caccavale
et al., 2010)
Fig. 18. Bilateral chronic central serous chorioretinopathy treated by mineralocorticoid-receptor antagonist. Fifty-three year-old male patient with bilateral chronic CSCR, as evi-
denced by RPE changes on fundus autoﬂuorescence (A and C) and ﬂuorescein angiography (B and D). SD-OCT showed a bilateral subretinal detachment (E, F), more pronounced in
the right eye (E) and intraretinal cystoid edema in the left eye consistent with the chronic form of CSCR (F). The patient was treated by oral eplerenone (50 mg/day for 1 month, then
25 mg/day) and was maintained under the lowest possible dose (25 mg/day). A progressive retinal reapplicationwas observed in both eyes, with diminution of intraretinal edema in
the left eye, maintained 6 months (G and H) and 18 months after initiation of treatment (I and J).
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3.1. The aldosterone/mineralocorticoid receptor pathway and
rationale for potential involvement in CSCR pathogenesis
CSCR is a one of the rare ophthalmic diseases that is aggravated
or even triggered by exogenous glucocorticoids (see 2.2.4).
Endogenous cortisol metabolism disturbances have also been
associated with CSCR (see 2.2.5) suggesting that glucocorticoids
favor the accumulation of ﬂuid under the retina in this speciﬁc
condition, instead of acting on its absorption as observed in mac-
ular edema of other origins (Sarao et al., 2014).
This paradox is not unique. In internal medicine, glucocorticoids
are used to reduce edema of numerous origins such as inﬂamma-
tion, infection, allergy, trauma and neurotoxicity. However, their
use is also associated with adverse side effects including water and
sodium retention. Indeed, the primary adrenal cortical steroid
hormones, aldosterone and cortisol, act through binding to the
structurally similar mineralocorticoid (MR) and glucocorticoid (GR)
receptors.
The MR and the 11ß-hydroxysteroid dehydrogenase type 2
(11ßHSD2) pre-receptoral enzyme are expressed in the kidney,
known as the classical mineralocorticoid-sensitive organ. Aldoste-
rone regulates sodium and ﬂuid reabsorption in the distal part of
the renal tubule, modulating body ﬂuid volume and blood pressure.
In particular, through MR activation, the sodium channel expres-
sion and distribution is regulated. The endogenous cortisol has
similar afﬁnity for GR and MR but synthetic or semi-synthetic
therapeutic glucocorticoids have been chemically modiﬁed to in-
crease their GR afﬁnity and reduce their MR afﬁnity. Therapeutic
glucocorticoids agents can also activate theMR in the kidney, whichresults in water retention in the intravascular compartment and
increased blood pressure. Combining these facts, the primary hy-
pothesis was that glucocorticoids could also potentially regulate
ion and water channels in the eye through MR activation, resulting
in the paradoxical pro-edematous effects of glucocorticoids in
CSCR.
Beside the kidney, other organs, tissues and cells express MR
and have been recognized as non-classical mineralocorticoid-sen-
sitive targets: heart, blood vessels, brain, adipose tissue, skin and
macrophages (Farman et al., 2010; Nguyen Dinh Cat and Jaisser,
2012). GR and MR are thus co-expressed in many cell types,
where they interact at molecular and functional levels, synergisti-
cally or competitively. As a consequence, the GR/MR balance is
crucial to control hydro-electrolytic regulation. In most tissues,
under physiologic conditions glucocorticoids occupy the MR at
basal levels and the over-activation of the MR pathway is patho-
genic (Gomez-Sanchez and Gomez-Sanchez, 2014).
Studies using transgenic mice demonstrated that activation of
the MR pathway per se induced hypertension and increased con-
tractile response to vasoconstrictors when the MR was over-
expressed in vessels, and arythmia when the MR was over-
expressed in the heart (Brown, 2013; Young and Rickard, 2015).
Furthermore, low doses of aldosterone have been shown to exert
direct effects on the vascular system by inducing oxidative stress,
inﬂammation, hypertrophic remodeling, ﬁbrosis and endothelial
dysfunction, demonstrating that activation of the MR pathway by
the ligand or the receptor activate different pathogenic mecha-
nisms (Briet and Schiffrin, 2013; Feldman and Gros, 2013; McCurley
and Jaffe, 2012). Following injury of vessels, MR activation has been
shown to promote smooth muscle cells ﬁbrosis via the activation of
the Placental Growth Factor (PGF)/VEGF Receptor 1 (VEGFR1)
Fig. 19. Chronic central serous chorioretinopathy treated by mineralocorticoid-
receptor antagonist. Chronic CSCR in the right eye of a ﬁfty-six year old male patient
with a dome-shaped pigment epithelial detachment (PED), an adjacent smaller ﬂat
PED, and a subretinal detachment (A). Four months after initial examination, the
subretinal detachment had slightly increased (B). The patient was treated by oral
eplerenone (50 mg/day for 1 month, then 25 mg/day) and was maintained under the
lowest possible dose (25 mg/day). Two months later, the dome-shaped PED had ﬂat-
tened, and the amount of subretinal ﬂuid had decreased (C). Six months after treat-
ment initiation, both the dome-shaped and the smaller PEDs remained ﬂatter than at
baseline and there was complete resolution of subretinal ﬂuid (D).
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pathogenic vascular remodeling, linking the Placental Growth
Factor (PGF) and MR in this process (McGraw et al., 2013). MR an-
tagonists also reduced experimental cerebral aneurysms through
the reduction of NOX4, Rac1, monocyte chemoattractant protein 1
(MCP-1), and matrix metalloproteinase 9 expression (Tada et al.,
2009). Vascular dilation can also be controlled by the MR
pathway through nitric oxide (Heylen et al., 2009).
Increasing evidence suggests that blocking MR activation can
have therapeutic value for endothelial dysfunction, atherosclerosis,
hypertension, heart failure and chronic kidney disease. In a model
of retinopathy due to prematurity, the MR/aldosterone pathway
was shown to directly stimulate retinal neo-angiogenesis and to
modulate retinal inﬂammation, with leukostasis and MCP-1
expression. In this model the antagonism of MR had anti-
angiogenic effects (Wilkinson-Berka et al., 2009), suggesting that
choroidal vasculopathy could result, at least in part, from MR
activation.
Gender differences in the outcome of post-myocardial infarction
remodeling, prevalence of hypertension and sudden death of car-
diac origin raised the hypothesis that vascular and heart tissues
may respond differently to the aldosterone/MR pathway activation
depending on the hormonal status. Indeed, in endothelial cells MR
regulates the expression of the pro-inﬂammatory intercellular
adhesion molecule-1 (ICAM-1), and this was shown to be modu-
lated by estrogens through interaction of estrogen receptors and
MR. This has been proposed as a possible mechanism protecting
premenopausal women from cardiovascular disease (Barrett
Mueller et al., 2014; Mihailidou and Ashton, 2014).
In the brain, MR participates in the processing of stressful in-
formation, indicating that both genomic and non-genomic MR
pathways play a role in stress resilience (Ter Heegde et al., 2015).
The brain MR/GR balance may also contribute to the hypothalamic-
pituitary-adrenal axis deregulation observed in depression
(Juruena et al., 2015).
MR and 11ßHSD2 are expressed in the neurosensory retina, the
RPE and the choroid, as observed in rats, monkeys and humans
(Fig. 11), placing the retina into the category of non-classical
mineralocorticoid-sensitive organs (Golestaneh et al., 2002;
Wilkinson-Berka et al., 2009; Zhao et al., 2010).
The exact mechanisms by which glucocorticoids exert their
anti-edematous effects on the retina have been partially elucidated.
But their role when edema has not originated from inﬂammatory
processes has not been explored sufﬁciently. Apart from the
recognized effects of glucocorticoids on junction proteins and on
the expression of several pro-inﬂammatory cytokines via NF-kB-
dependent regulation (Chinenov et al., 2013; Salvador et al.,
2014), glucocorticoids also act on ion and water channels expres-
sion and distribution in retinal glial Müller cells (Zhao et al., 2011).
Moreover, commonly used glucocorticoids (i.e. triamcinolone ace-
tonide and dexamethasone sodium diphosphate) injected at
different doses in normal or inﬂamed rat eyes regulate differently
the expression and cellular distribution of Kir4.1 (Inwardly recti-
fying Kþ channel 4.1) and AQP4 (Aquaporin 4), two channels
expressed in retinal glial Müller cells and known to contribute to
retinal edema. Similar regulations were observed on humanMüller
cells in vitro (Zhao et al., 2011). The differential effects of gluco-
corticoids according to the drug type and dose, is likely related to
the different GR/MR afﬁnity proﬁle of the different agents.
3.2. The different MR antagonists
The MR has two natural ligands, aldosterone and cortisol (or
corticosterone, its equivalent in rodents) that bind to the MR with
the same afﬁnity. Blood cortisol levels are much higher thanaldosterone. In tissues where the 11ßHSD2 is expressed, MR is
protected from being occupied by glucocorticoids, via the action of
11ßHSD2, which metabolizes cortisol into cortisone, that has a
much lower afﬁnity for the MR. In most of non-epithelial MR tar-
gets, 11ßHSD2 is not expressed and thus glucocorticoids occupy the
MR (Fuller et al., 2012; Odermatt and Atanasov, 2009).
The ﬁrst steroidal competitive MR antagonist drug was spi-
ronolactone, approved for the treatment of hypertension 55 years
ago. It is a potent but non-speciﬁc MR antagonist, as it also interacts
with progesterone receptors, leading to dose-dependent hormonal
side-effects such as gynecomastia, erectile dysfunction, a possible
decrease in libido, and menstrual irregularities (Funder, 2013).
Spironolactone is a prodrug, converted by the liver into an array of
active metabolites (including canrenone) whose half-life is inferior
to 7 h (Gardiner et al., 1989).
Eplerenone, designed to reduce the hormonal effects of spi-
ronolactone, was approved by the Food and Drug Administration, in
2002. Although it antagonizes the MR more selectively than spi-
ronolactone, it has a 40-fold lower afﬁnity for the MR and is
therefore a less potent MR antagonist than spironolactone. Epler-
enone has no active metabolites and its plasma half-life is 3 h (Cook
et al., 2003).
Regarding their action on electrolytes balance, hyperkalemia is a
potential adverse consequence of both spironolactone and epler-
enone therapy, but is clinically relevant only in patients with
A. Daruich et al. / Progress in Retinal and Eye Research 48 (2015) 82e118110impaired renal function. Plasma potassium concentrations should
be monitored at baseline and periodically according to the drug
manufacturer's instructions.
Since the publication of groundbreaking clinical studies
showing that spironolactone and eplerenone reduced the
morbidity and mortality in patients with heart failure (Funder,
2005; Pitt et al., 2003, 1999), extensive research has been con-
ducted to discover other classes of MR antagonists devoid of renal
effects. Recently, the new non-steroidal MR antagonist BAY 94-
8862 showed at least an equivalent efﬁcacy to spironolactone in
decreasing biomarkers of hemodynamic stress, and was associated
with lower incidences of hyperkalemia and renal function wors-
ening (Bauersachs, 2013).
The ocular biodisponibility of spironolactone and eplerenone
after systemic administration has not been studied but spi-
ronolactone induces the expression of the P-glycoprotein, a drug
efﬂux protein that regulates the bloodebrain barrier, and is one of
its ligands (Ghanem et al., 2006).Fig. 20. Advanced bilateral chronic central serous chorioretinopathy treated by minera
descending hypo-autoﬂuorescent tracks (A and B) indicating a severe chronic CSCR with diff
retinal pigment epitheliopathy”. Enhanced depth-imaging OCT revealed intraretinal cystoid e
right eye (C), and severe cystoid macular degeneration with RPE hyperplasia and atrophy in
during 1 month, then 25 mg/day), a major decrease in intraretinal cystoid edema was observ
was continued, and 12 months after initiation the favorable morphological effect was still3.3. Hypothesis: links between CSCR characteristics and MR/
aldosterone pathway pathogenesis
The majority of CSCR cases occur in men and post-menopausal
women. CSCR is associated with an increased risk of coronary
events (Chen et al., 2014) and hypertension (Haimovici et al., 2004).
These patients are also at higher risk of personality disorders
associated with stress and anxiety susceptibility (Carlesimo et al.,
2014; Piskunowicz et al., 2014) (Fig. 12).
Evidences also converge towards the recognition that CSCR
pathogenesis involves the choroidal vasculature and its vasomotor
control (Guyer et al., 1994; Tittl et al., 2005). To date, the results
obtained by our research group indicate that MR pathway activa-
tion is involved in the development of CSCR, be it spontaneous, or
triggered by endo- or exogenous steroids. We speculate that MR
over- or inappropriate activation due to genetic, epigenetic or
environmental factors, could induce in susceptible individuals a
higher risk for hypertension, coronary events, psychologicallocorticoid-receptor antagonist. Seventy-seven year-old man with bilateral oblong
use decompensation of the retinal pigment epithelium, formerly referred to as “Diffuse
dema and shallow pigment epithelial detachment with hyper-reﬂective content on the
the left eye (D). Three months after initiation of oral eplerenone therapy (50 mg/day
ed, with a limited effect on the pigment epithelial detachment (E and F). The treatment
observed (G and H).
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glucocorticoids.
3.4. Scientiﬁc evidences
3.4.1. Preclinical studies
Acute activation of the MR pathway in rat eyes has been pre-
viously simulated using intraocular injections of aldosterone or
high-dose corticosterone (the endogenous glucocorticoid hormone
in rodents). Intravitreal injections of aldosterone enhanced the
expression of the Naþ channel ENaC-a (Epithelial Naþ channel-a),
the Kþ channel Kir4.1, as well as the water channel AQP4. It pro-
moted additional localization of Kir4.1 and AQP4 toward the outer
limitingmembrane, contributing to the accumulation of ﬂuid in the
outer retina (Fig. 12). Intravitreal aldosterone also induced swelling
of retinal glial Müller cells (Fig. 13A and B). Aldosterone-induced
MR-dependent Kir4.1 and AQP4 regulation was also observed on
human Müller glial cell lines (Zhao et al., 2010). At choroidal level,
intravitreal administration of aldosterone provoked vasodilation
and leakage of choroidal vessels with elongation of retinal pigment
epithelial cells microvilli (Fig. 13AeE), increased choroidal thick-
ness and accumulation of subretinal ﬂuid, mimicking the CSCR
phenotype. The spectrum of genomic and non-genomic regulatory
mechanisms underlying these reactions has not been fully
described. To date, aldosterone has been shown to regulate the
endothelium-derived hyperpolarizing factor (EDHF) through the
up-regulation of the small-conductance Ca2þ-activated Kþ channel
2.3 (K(Ca)2.3), expressed in choroidal endothelial cells but not in
the retinal vessel endothelium (Zhao et al., 2012) (Fig. 14).
A conditional double transgenic mouse model in which induc-
ible MR over-expression is restricted to the endothelium (DT-
veCadhMR) was generated. It presented a mild hypertension with
no basal endothelial dysfunction, but an enhanced concentration-
dependent arterial contraction in response to vasoconstrictors
such as phenylephrine (Nguyen Dinh Cat et al., 2010). Moreover, in
these mice, choroidal thickness was spontaneously increased and
choroidal vessels were dilated, associated with focal disruption of
RPE tight junctions and RPE detachments (Fig. 15) (unpublished
results from N. Farman and F. Jaisser). Interestingly, CSCR is also
associated with the use of sympathomimetic agents, as detailed in
2.2.8 (Michael et al., 2003; Pierce and Lane, 2009).
In conclusion, preclinical studies have evidenced that MR over-
activation via either overexpression of the receptor in the vessels,
or acute administration of its ligands (aldosterone and corticoste-
rone) produced choroidal and RPE changes, and SRD.
3.4.2. Preliminary clinical results
Based on these preclinical results, MR antagonists were pro-
posed as a treatment for CSCR patients with persistent subretinal
ﬂuid.
Two interventional, uncontrolled, prospective case series were
conducted testing either eplerenone (25 mg daily for 1 week, then
50 mg for 1e3 months) in 13 patients, or spironolactone (50 mg
daily for up to 3 months) in 18 patients. Prior to enrollment all
subjects had been observed to have subretinal ﬂuid for at least 3
months. In both studies a signiﬁcant reduction in foveal subretinal
ﬂuid compared to baseline levels was observed three months after
initiation of treatment, from 155 mm to 36 mm (p < 0.01) and from
219 mm to 100 mm (p < 0.01), respectively (Bousquet et al., 2013;
Herold et al., 2014). In both studies this anatomical recovery was
associated with an increase in LogMAR visual acuity, from 0.52 to
0.27 (p < 0.01) and from 0.32 to 0.22 (p ¼ 0.04), respectively. At 3
months, a total resolution of subretinal ﬂuid was observed in 67% of
patients treated with eplerenone (Bousquet et al., 2013).
Retrospectively, we reviewed the medical records of 46 eyesfrom 36 patients (31 male, 5 women, mean age 53.1 years) with
non-resolving CSCR after 4 months follow-up (reduced to 2 months
in case of a recurrent episode), treated by oral eplerenone or spi-
ronolactone (25e50 mg/day). After 3 months of treatment, foveal
subretinal ﬂuid decreased from 97 mm to 42 mm (p < 0.001), central
macular thickness decreased from 334 mm to 279 mm (p < 0.001)
and choroidal thickness decreased from 482 mm to 456 mm
(p < 0.001) compared to baseline levels (unpublished data) (Figs. 16
and 17). These encouraging results have been reproduced in a
double-blinded randomized clinical trial examining the treatment
effect of spironolactone versus placebo (Bousquet et al., n.d.).
In light of these results, the role of MR antagonists in the
treatment of CSCRwill need to be better deﬁned, in terms of disease
stage, persistence of subretinal ﬂuid or the combination with
alternative therapeutic approaches such as PDT. To date, various
durations of treatment by MR antagonists have been evaluated in
acute cases with persistent subretinal ﬂuid, and in chronic cases. In
real-life conditions selected chronic patients are being treated
under long-term, low-dose MR antagonist therapy as illustrated in
Fig. 18e20.
4. Conclusions and future directions
Improved and innovative technologies allowing better imaging
of the choroid and choroidal vasculature have and will continue to
advance our understanding of CSCR pathophysiology. Conse-
quently, the spectrum of disease phenotypes related to CSCR con-
tinues to expand with important implications in the genetic
approach of CSCR and in the design of therapeutic interventional
studies. Whilst several treatment options are available, randomized
placebo controlled studies are required to guide optimized treat-
ment schemes depending on phenotypes. Results from funda-
mental research studies prompted the hypothesis that the
mineralocorticoid pathway could be involved in CSCR. In this re-
view, we have aimed to give an overview of this hypothesis,
bridging the ocular expression of this disease with other conse-
quences of inappropriate MR pathway activation manifesting in
CSCR patients. These observations indicate that MR antagonism is a
potential minimally invasive therapy for CSCR as shown by the
strong treatment effect in the ﬁrst clinical trials of oral MR antag-
onists. But their exact place in the therapeutic arsenal remains to be
determined. The exact dose and duration of treatment depending
on the clinical forms of the disease should also be evaluated. Finally,
the optimal route of administration must be developed. Further
studies aiming at identifying downstream pathways and regulatory
molecular targets in the choroid and the RPE are currently ongoing.
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